<SEC-DOCUMENT>0001178913-24-001206.txt : 20240403
<SEC-HEADER>0001178913-24-001206.hdr.sgml : 20240403
<ACCEPTANCE-DATETIME>20240403070019
ACCESSION NUMBER:		0001178913-24-001206
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20240403
FILED AS OF DATE:		20240403
DATE AS OF CHANGE:		20240403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		24816822

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2431235.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
  <div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-size: 14pt;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-size: 14pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> <br>
      </font></div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-size: 14pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">&#160;UNITED STATES&#160;</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;&#160;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt;">
      <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C.&#160;20549</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt;">
      <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold;">FORM 6-K</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Report of Foreign Private Issuer</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">of&#160;the Securities Exchange Act of 1934</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">For the month of April 2024<br>
      Commission File No.:001-35773</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt;">
      <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold;">REDHILL BIOPHARMA LTD.</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(Translation of registrant&#8217;s name into English)</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">21 Ha&#8217;arba&#8217;a Street, Tel Aviv, 6473921, Israel</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(Address of principal executive offices)</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or
      Form 40-F.&#160;&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Form 20-F&#160;&#9746;&#160;&#160; &#160;&#160; &#160; Form 40-F&#160;&#9744;</div>
    <div style="text-indent: 14.2pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by Regulation
      S-T Rule 101(b)(1): ____&#160;</div>
    <div style="text-indent: 28.35pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by Regulation
      S-T Rule 101(b)(7): ____</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">On March 29, 2024, RedHill Biopharma Ltd. (&#8220;RedHill&#8221; or the &#8220;Company&#8221;), a specialty biopharmaceutical company, entered into a
      Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with private investors&#160; (&#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering directly to the Purchasers, (i) 2,144,487 American Depositary
      Shares (&#8220;ADSs&#8221;), each ADS representing four hundred (400) ordinary shares, par value NIS 0.01 per share, of the Company and (ii) warrants to purchase up to an aggregate of 2,144,487 ADSs, at a purchase price of $0.58289 per ADS and accompanying
      warrant. The warrants will have an exercise price of $0.75 per ADS, will be immediately exercisable upon issuance and have a term of five years following the issuance date. The closing of the offering is expected to occur on or about April 3, 2024,
      subject to the satisfaction of customary closing conditions.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">No placement agent was used in connection with the offering.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The gross proceeds to the Company from the offering are expected to be $1.25 million, before deducting offering expenses payable
      by the Company.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The securities described were offered by the Company pursuant to a &#8220;shelf&#8221; registration statement on Form F-3 (File No.
      333-258259) previously filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 29, 2021, and declared effective by the SEC on August 9, 2021. The offering of the securities is made only by means of a prospectus, including a prospectus
      supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement
      and accompanying prospectus may be obtained, when available, on the SEC&#8217;s website at http://www.sec.gov.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Attached hereto and incorporated by reference herein are the following exhibits:</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="exhibit_1-1.htm">Exhibit 1.1: Form of
        Securities Purchase Agreement. <br>
      </a></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="exhibit_1-2.htm">Exhibit 1.2: Form of
        Warrant.</a></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="exhibit_5-1.htm">Exhibit 5.1: Opinion
        of Goldfarb Gross Seligman &amp; Co.</a></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="exhibit_5-2.htm">Exhibit 5.2: Opinion
        of Haynes and Boone, LLP.</a></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="exhibit_5-1.htm">Exhibit 23.1: Consent
        of Goldfarb Gross Seligman &amp; Co. (included in Exhibit 5.1).</a></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="exhibit_5-2.htm">Exhibit 23.2: Consent
        of Haynes and Boone, LLP (included in Exhibit 5.2).</a></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This Form 6-K shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein,
      nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This Form 6-K is hereby incorporated by reference into the Company&#8217;s Registration Statements on Form S-8 filed with the
      Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File
      No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845) and on June 29, 2023 (File No. 333-273001) and its Registration
      Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on July 29, 2021 (File No. 333-258259), August 4, 2023 (File No. 333-273709) and on October 13, 2023 (File No. 333-274957), as amended.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <br>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SIGNATURES</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Pursuant to the requirements of&#160;the&#160;Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
      behalf by the undersigned, thereunto duly authorized.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="zec17718bb2ac4e3e800efa39c3b2d9f1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
          <td style="vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">REDHILL BIOPHARMA LTD.</div>
          </td>
          <td style="width: 19.62%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
          <td style="vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">(the &#8220;Registrant&#8221;)</div>
          </td>
          <td style="width: 19.62%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
          <td style="width: 24.5%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
          <td style="width: 19.62%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Date: April 3, 2024</div>
          </td>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">By:</div>
          </td>
          <td nowrap="nowrap" style="width: 24.5%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">/s/ Dror Ben-Asher</div>
          </td>
          <td style="width: 19.62%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">Name:</div>
          </td>
          <td nowrap="nowrap" style="width: 24.5%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;Dror Ben-Asher</div>
          </td>
          <td style="width: 19.62%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">Title:</div>
          </td>
          <td style="width: 24.5%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">Chief Executive Officer</div>
          </td>
          <td style="width: 19.62%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>exhibit_1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> </u>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 1.1</u><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><br>
      SECURITIES PURCHASE AGREEMENT</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">This SECURITIES PURCHASE AGREEMENT (the &#8220;<u>Agreement</u>&#8221;), dated as of March 29, 2024, between RedHill Biopharma Ltd., a company
      organized under the laws of the State of Israel (the &#8220;<u>Company</u>&#8221;), and each investor identified on the signature pages hereto (each, including its successors and assigns, an &#8220;<u>Investor</u>&#8221; and collectively, the &#8220;<u>Investors</u>&#8221;). Subject to
      the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;), the Company desires to issue and sell to each Investor, and each
      Investor, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">THE PARTIES HEREBY AGREE AS FOLLOWS:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Purchase and Sale of the Securities</u>.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Sale and Issuance of the Securities</u>.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to the Closing (as defined below), the Company shall have authorized (i) the sale and issuance to the
        Investors of the American Depositary Shares (each an &#8220;<u>ADS</u>&#8221; and, collectively, the &#8220;<u>ADSs</u>&#8221;, and such Ordinary Shares (as defined below) represented by the ADSs, the &#8220;<u>Shares</u>&#8221;), each representing four hundred (400) ordinary shares
        of the Company, par value NIS 0.01 per share (the &#8220;<u>Ordinary Shares</u>&#8221;), issued pursuant to the Deposit Agreement, dated as of December 26, 2012, among the Company, The Bank of New York Mellon, as Depositary (the &#8220;<u>Depositary</u>&#8221;) and the
        owners and holders of ADSs from time to time, as such agreement may be amended or supplemented, (ii) the sale and issuance to the Investors of the Warrants (as defined below), and (iii) the issuance of the ADSs (the &#8220;<u>Warrant ADSs</u>&#8221;) upon
        exercise of the Warrants, and the Ordinary Shares represented by the ADSs issuable upon exercise of the Warrants (the &#8220;<u>Warrant Shares</u>&#8221;). The &#8220;<u>Subscription Amount</u>&#8221; means, as to each Investor, the aggregate amount to be paid for ADSs
        and Warrants purchased hereunder as specified below such Investor&#8217;s name on the signature page of this Agreement and next to the heading &#8220;Subscription Amount,&#8221; in United States dollars and in immediately available.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Investors agree to purchase at the Closing, and
        the Company agrees to sell and issue to the Investors at the Closing (i) the number of ADSs set forth on the signature page hereto, (ii) pre-funded warrants (the &#8220;<u>Pre-Funded Warrants</u>&#8221;) in the form attached as Exhibit A hereto, and (iii)
        ordinary share purchase warrants (the &#8220;<u>Ordinary Share Warrants</u>&#8221; and together with the Pre-Funded Warrants, the &#8220;<u>Warrants</u>&#8221;) in the form attached as <u>Exhibit B</u> hereto, to purchase up to a number of ADSs equal to 100% such
        Investor&#8217;s ADSs, at an exercise price of $0.75 per ADS, subject to adjustments therein, at a combined purchase price of $0.58289 per ADS and the accompanying Ordinary Share Warrant (&#8220;<u>Per ADS Purchase Price</u>&#8221;). This Agreement, the Warrants,
        and all exhibits and schedules thereto and hereto and any other documents or agreements executed with the transactions contemplated hereunder are collectively referred to herein as the &#8220;<u>Transaction Documents</u>.&#8221;</font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Closing; Delivery</u>. On the Closing Date,
        upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Investors, severally and not jointly, the ADSs (and/or, if applicable, the Pre-Funded Warrants) and Ordinary Share Warrants equal to the aggregate
        Subscription Amount of the Investors on the signature pages hereto. Subject to the terms and conditions of this Agreement, the<font style="font-weight: bold;">&#160;</font>issuance of the ADSs (and/or, if applicable, the Pre-Funded Warrants) and
        Ordinary Share Warrants shall take place remotely via the exchange of documents and signatures on a day on which the Nasdaq Capital Market (or such other principal trading market or exchange on which the ADS is listed for trading, or any successors
        thereto) is open for trading (such day, a &#8220;<u>Trading Day</u>&#8221;) on which all conditions set forth in this Agreement have been satisfied (or waived as permitted herein) at such time as the Company and the Investors mutually agree upon, orally or in
        writing (which time and place are designated as the &#8220;<u>Closing</u>&#8221; and such date, the &#8220;<u>Closing Date</u>&#8221;). Each Investor&#8217;s Subscription Amount shall be made available for &#8220;Delivery Versus Payment&#8221; (&#8220;DVP&#8221;) settlement with the Company or its
        designee. The Company shall deliver to each Investor its respective ADSs and/or Pre-Funded Warrant (as applicable to such Investor) as determined pursuant to Section 1.2(a), and the Company and each Investor shall deliver the other items set forth
        in Sections 1.2(a) and (b) deliverable at the Closing.&#160; Notwithstanding anything herein to the contrary, to the extent that an Investor determines, in its sole discretion, that such Investor&#8217;s Subscription Amount would cause the Investor&#8217;s
        (together with such Investor&#8217;s affiliates, and any person acting as a group together with such Investor or any of such Investor&#8217;s affiliates) beneficial ownership of Ordinary Shares or Ordinary Shares underlying the ADSs to exceed the Beneficial
        Ownership Limitation, or as such Investor may otherwise choose, in lieu of purchasing ADSs, such Investor may elect, by so indicating such election prior to their issuance, to purchase Pre-Funded Warrants in lieu of ADSs in such manner to result in
        the same aggregate purchase price being paid by such Investor to the Company. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% (or, with respect to each Investor, at the election of such Investor, 9.99%) of the number of Ordinary Shares
        outstanding immediately after giving effect to the issuance of the ADS and the Warrants on the Closing Date.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On or prior to the Closing, the Company shall deliver to each Investor the following:</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 157.5pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;this Agreement duly executed by the Company;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 157.5pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a copy of the irrevocable instructions to the Depositary instructing the Depositary to deliver on an
        expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) ADSs equal to each Investor&#8217;s Subscription Amount divided by the Per ADS Purchase Price, registered in the name of such Investor (minus the
        number of ADSs issuable upon exercise of such Investor&#8217;s Pre-Funded Warrants, if applicable);</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 157.5pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;an Ordinary Share Warrant registered in the name of such Investor to purchase up to a number of ADSs
        equal to 100% of the sum of such Investor&#8217;s ADSs and Pre-Funded Warrants on the date hereof, with an exercise price equal to $0.75, subject to adjustment therein;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 157.5pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;if applicable, a Pre-Funded Warrant registered in the name of such Investor to purchase up to a number of
        ADSs equal to the portion of such Investor&#8217;s Subscription Amount applicable to Pre-Funded Warrants divided by the Per ADS Purchase Price minus $0.001, with an exercise price equal to $0.001 per ADS, subject to adjustment therein;</font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 162pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a) the base prospectus (the &#8220;<u>Prospectus</u>&#8221;) forming a part of the effective registration statement
        (the &#8220;<u>Registration Statement</u>&#8221;) on Form F-3 (File No. 333-258259) filed with the Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;), including all information, documents and exhibits filed with or incorporated by reference therein
        and (b) the prospectus supplement (the &#8220;<u>Prospectus Supplement</u>&#8221;) to the Prospectus, complying with Rule 424(b) of the Securities Act, including all information, documents and exhibits filed with or incorporated by reference therein, that is
        filed with the Commission and delivered by the Company to each Investor at the Closing; and</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 157.5pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;wire instructions for a bank account designated by the Company.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On or prior to the Closing, each Investor shall deliver to the Company the following:</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 13.5pt; margin-left: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; this Agreement duly executed by such Investor; and</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 121.5pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the Investor&#8217;s Subscription Amount for the ADSs and the Warrants by wire transfer to
        the bank account designated by the Company; and</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 121.5pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; a duly executed, correct, complete and accurate IRS Form W-8 or W-9 (or any
        successor form), as applicable.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Use of Proceeds</u>.&#160; The Company covenants
        and agrees that it shall use the proceeds of the sale of the ADSs and the Warrants hereunder for general corporate purposes and working capital, and to pay any fees and expenses in connection with the issuance of the ADSs and the Warrants.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Representations and Warranties of the Company</u>.
        Except as set forth in the SEC Reports (as defined herein), the Company represents and warrants to the Investor on the date hereof and on the Closing Date that:</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Organization, Good Standing and Qualification</u>.&#160;

        The Company is a corporation duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation. The Company is duly qualified to transact business and is in good standing in each jurisdiction, except where
        the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of this Agreement or the Warrants, (ii) a
        material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiary, taken as a whole, or (iii) a material adverse effect on the Company&#8217;s ability to perform in
        any material respect on a timely basis its obligations under this Agreement or the Warrants (any of (i), (ii) or (iii), a &#8220;<u>Material Adverse Effect</u>&#8221;).</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Capitalization and Voting Rights</u>. The
        capitalization of the Company and voting rights of the Ordinary Shares are identified in the SEC Reports and the Company&#8217;s Articles of Association (the &#8220;<u>Articles</u>&#8221;), respectively.</font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Valid Issuance of the Securities; Registration</u>.&#160;

        The ADSs and the Shares being purchased by the Investors hereunder, when issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable
        and will be free of restrictions on transfer other than restrictions on transfer under this Agreement. The Warrant Shares, upon issuance in accordance with the terms of the Warrants, will be duly and validly issued, fully paid and nonassessable and
        will be free of restrictions on transfer other than restrictions on transfer under this Agreement. The Warrants being purchased by the Investors hereunder, when paid for and issued in accordance with this Agreement, will constitute valid and
        binding obligations of the Company, enforceable against the Company in accordance with their terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally
        and subject to general principles of equity. The maximum number of Shares and the Warrant Shares have been duly and validly reserved for issuance from the Company&#8217;s duly authorized capital stock. The Company has prepared and filed the Registration
        Statement in conformity with the requirements of the Securities Act, which became effective on August 9, 2021, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement.&#160; The
        Company was at the time of the filing of the Registration Statement eligible to use Form F-3. The Company and the Depositary have prepared and filed with the Commission a registration statement relating to ADSs on Form F-6 (File No. 333-268713) for
        registration under the Securities Act (the &#8220;<u>ADS Registration Statement</u>&#8221;) which became effective on December 8, 2022. The Registration Statement and ADS Registration Statement are effective under the Securities Act and no stop order
        preventing or suspending the effectiveness of the Registration Statement or the ADS Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been
        instituted or, to the knowledge of the Company, are threatened by the Commission.&#160; The Company, if required by the rules and regulations of the Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b).&#160; At the
        time the Registration Statement and the ADS Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and the ADS Registration Statement and any amendments
        thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
        necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was filed and at the Closing Date, conformed and will conform
        in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
        circumstances under which they were made, not misleading.&#160; The Company is eligible to use Form F-3 under the Securities Act and meets the transaction requirements as set forth in General Instruction I.B.1 of Form F-3.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Governmental Consents</u>. No consent,
        approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of the Company or its subsidiary (the &#8220;<u>Subsidiary</u>&#8221;) is required in
        connection with the consummation of the transactions contemplated by the Transaction Documents, except such as may be required under the Act, the rules of the Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) or state securities or blue sky laws,
        if applicable (collectively, the &#8220;<u>Required Approvals</u>&#8221;).</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Li</u><u>tigation</u>.&#160;&#160; Other as disclosed in
        the SEC Reports, there is no action, suit, proceeding or investigation pending or, to the Company&#8217;s knowledge, currently threatened against the Company or the Subsidiary that questions the validity of this Agreement or the Warrants, or the right of
        the Company to enter into such agreements, or to consummate the transactions contemplated thereunder, or that might result, either individually or in the aggregate, in any material adverse changes in the assets, condition or affairs of the Company
        or the Subsidiary, financially or otherwise, or any change in the current equity ownership of the Company or the Subsidiary, nor is the Company or the Subsidiary aware that there is any basis for the foregoing. The foregoing includes, without
        limitation, actions, suits, proceedings or investigations pending or threatened (or any basis therefor known to the Company) involving the prior employment of any of the Company&#8217;s or the Subsidiary&#8217;s employees, their use in connection with the
        Company&#8217;s or the Subsidiary&#8217;s business of any information or techniques allegedly proprietary to any of their former employers or their obligations under any agreements with prior employers.&#160; Neither the Company nor the Subsidiary is a party or
        subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no action, suit, proceeding or investigation by the Company or the Subsidiary currently pending or that the
        Company intends to initiate.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Compliance with Other Instruments</u>.&#160;
        Neither the Company nor the Subsidiary is in violation, default, conflict or breach in any respect of any provision of its Articles or equivalent corporate documents, or in any material respect of any instrument, judgment, order, writ, decree,
        privacy policy (each of which has been provided to special counsel to each Investor, as applicable) or contract to which it is a party or by which it is bound, or, to its knowledge, of any provision of any federal or state statute, rule or
        regulation applicable to the Company or the Subsidiary (including, without limitation, those related to privacy, personally identifiable information or export control), subject to the Required Approvals.&#160; The execution, delivery and performance of
        the Transaction Documents, and the consummation of the transactions contemplated hereby and thereby will not result in any such violation, default, conflict or breach, nor will such consummation constitute, with or without the passage of time and
        giving of notice, subject to the Required Approvals, an event that results in (a) the creation of any lien, charge or encumbrance upon any assets of the Company, or (b) the suspension, revocation, impairment, forfeiture, or nonrenewal of any
        material permit, license, authorization, or approval applicable to the Company, its respective business or operations or any of its respective assets or properties, except in the case of each of clauses (a) and (b), such as could not, individually
        or in the aggregate, have or reasonably be expected to have a Material Adverse Effect.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Financial Statements</u>.&#160; The Company has
        directed each Investor to review its audited and unaudited financial statements (collectively, the &#8220;<u>Financial Statements</u>&#8221;) included in its reports, schedules, forms, statements and other documents required to be filed by the Company under
        the Act and the Exchange Act of 1934, as amended (the &#8220;<u>Exchange Act</u>&#8221;), including pursuant to Section 13(a) or 15(d) thereof (<font style="color: rgb(0, 0, 0);">the foregoing materials, including the exhibits thereto and documents
          incorporated by reference therein, being collectively referred to herein as the </font>&#8220;<u>SEC Reports</u>&#8221;).</font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Material Changes</u>.&#160; Since the date of the
        Company&#8217;s most recently filed annual report under the Exchange Act, except in the case of each of clauses (a) through (e) and, as disclosed in the SEC Reports, such as could not, individually or in the aggregate, have or reasonably be expected to
        have a Material Adverse Effect, there has not been:</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any change in the assets, liabilities, financial condition or operating results of the Company or the
        Subsidiary from that reflected in the Financial Statements;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any damage, destruction or loss, whether or not covered by insurance, materially and adversely affecting the
        assets, properties, financial condition, operating results, prospects or business of the Company or the Subsidiary (as such business is presently conducted and as it is proposed to be conducted);</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any sale, assignment or transfer of any patents, trademarks, copyrights, trade secrets or other intangible
        assets;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any loans or guarantees made by the Company or the Subsidiary to or for the benefit of its employees,
        officers or directors, or any members of their immediate families, other than travel advances and other advances made in the ordinary course of its business; or</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to the Company&#8217;s knowledge, any other event or condition of any character that might materially and
        adversely affect the assets, properties, financial condition, operating results or business of the Company or the Subsidiary (as such business is presently conducted and as it is proposed to be conducted).</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Representations and Warranties of the Investor</u>s.&#160;

        Each Investor hereby represents and warrants to the Company on the date hereof and on the Closing Date that:</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Authorization</u>.&#160; Such Investor is either an
        individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and
        authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. Such Investor has full power and authority to enter into the Transaction
        Documents, and each Transaction Document to which the Investor is a party has been duly executed and delivered by the Investor and constitutes its valid and legally binding obligation, enforceable against such Investor in accordance with its terms
        except (a)&#160;as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, and (b)&#160;as limited by laws relating to the availability of specific
        performance, injunctive relief or other equitable remedies. The execution, delivery and performance of this Agreement by such Investor and the consummation by it of the transactions contemplated thereby have been duly and validly authorized by all
        necessary all necessary corporate, partnership, limited liability company or similar legal action, as applicable, and no further consent or authorization of such Investor is required.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The execution, delivery and performance of this Agreement by such Investor and the consummation by such Investor of the transactions
      contemplated thereby will not (a) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, any material agreement to which such Investor is a party or by which such Investor is bound or to
      which any of the property or assets of such Investor is subject, (b) conflict with or result in any violation of the provisions of the organizational documents of such Investor, or (c) violate any statute, order, rule or regulation of any court or
      governmental agency or body having jurisdiction over such Investor or the property or assets of such Investor, except in the case of clauses (a) and (c), for such conflicts, breaches, violations or defaults as would not prevent the consummation of
      the transactions contemplated by this Agreement.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Purchase Entirely for Own Account</u>.&#160; This
        Agreement is made with such Investor in reliance upon such Investor&#8217;s representation to the Company, which by such Investor&#8217;s execution of this Agreement such Investor hereby confirms, that the Securities will be acquired for investment for such
        Investor&#8217;s own account, not as a nominee or agent, and not with a view to the distribution of any part thereof in violation of the Act or any applicable federal or state securities laws, and that such Investor has no present intention of selling,
        granting any participation in or otherwise distributing the same. By executing this Agreement, such Investor further represents that such Investor does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer
        or grant participations to such person or to any third person, with respect to any of the Securities. Such Investor is acquiring the Securities hereunder in the ordinary course of its business.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Disclosure of Information</u>.&#160; Such Investor
        believes it has received all the information it considers necessary or appropriate for deciding whether to purchase the Securities. Such Investor further represents that it has had an opportunity to ask questions and received answers from the
        Company regarding the terms and conditions of the offering of the Securities, the merits and risks of investing in the Securities and the business, properties, prospects and financial condition of the Company. Such Investor has sought such
        accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Investment Experience</u>.&#160; Such Investor,
        either alone or together with its representatives, is an investor in securities of companies in the development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge,
        sophistication and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Securities and has so evaluated the merits and risks of such investment.&#160; If other than an individual,
        Investor also represents it has not been organized for the purpose of acquiring the Securities.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Investor Status and Experience</u>.&#160; At the
        time such Investor was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be either (i) an &#8220;accredited investor&#8221; within the meaning of Rule 501(a)(1), (a)(2), (a)(3),
        (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Act or (ii) a &#8220;qualified institutional buyer&#8221; as defined in Rule 144A(a) under the Securities Act.&#160; The Investor is not a registered broker dealer registered under Section 15(a) of the Exchange
        Act, or a member of the Financial Industry Regulatory Authority, Inc. or an entity engaged in the business of being a broker dealer.</font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; text-indent: 72pt;"><font style="font-family: 'Times New Roman',Times,serif;">3.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Prohibited Transactions</u>. The Investor has not, directly or indirectly, and no Person acting on behalf
        of or pursuant to any understanding with the Investor has, engaged in any purchases or sales in the securities, including derivatives, of the Company (including, without limitation, any Short Sales (a &#8220;<u>Transaction</u>&#8221;) involving any of the
        Company&#8217;s securities) since the time that the Investor was first contacted by the Company or any other Person regarding an investment in the Company. The Investor covenants that neither it nor any Person acting on its behalf or pursuant to any
        understanding with the Investor will engage, directly or indirectly, in any Transactions in the securities of the Company (including Short Sales) prior to the time the transactions contemplated by the Transaction Documents.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Exculpation Among Investors</u>.&#160; The Investor
        acknowledges that it is not relying upon any person, firm or corporation in making its investment or decision to invest in the Company.&#160; Neither the Investor nor any of its controlling persons, officers, directors, partners, agents or employees
        shall be liable to any other equity holder in the Company for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase of the Securities.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Foreign Investors</u>.&#160; If the Investor is not
        a United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code), the Investor hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to
        subscribe for the Securities or any use of this Agreement, including (i)&#160;the legal requirements within its jurisdiction for the purchase of the Securities, (ii)&#160;any foreign exchange restrictions applicable to such purchase, (iii)&#160;any governmental
        or other consents that may need to be obtained, and (iv)&#160;the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of the Securities. The Investor&#8217;s subscription and payment for
        and continued beneficial ownership of the Securities will not violate any applicable securities or other laws of the Investor&#8217;s jurisdiction.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Residence</u>.&#160; If the Investor is an
        individual, then the Investor resides in the state or province identified in the address of the Investor set forth on the signature page hereto; if the Investor is a partnership, corporation, limited liability company or other entity, then the
        office or offices of the Investor in which its principal place of business is identified in the address or addresses of the Investor set forth on the signature page hereto.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Certain Fees</u>. No fees or commissions are
        or will be payable by such Investor to brokers, finders or investment bankers with respect to the purchase of any of the Securities or the consummation of the transactions contemplated by the Transaction Documents. The Investor agrees that it will
        indemnify and hold harmless the Company from and against any and all claims, demands or liabilities for broker&#8217;s, finder&#8217;s, placement, or other similar fees or commissions incurred by such Investor or alleged to have been incurred by such Investor
        in connection with the purchase of the Securities or the consummation of the transactions contemplated by the Transaction Documents.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Information</u>. Such Investor shall cooperate
        reasonably with the Company to provide any information necessary for the Company to make any applicable filings, including but not limited to, filings with the SEC and pursuant to applicable state securities laws.</font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">3.12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Shareholder Agreements</u>.&#160; Such Investor is not, and at the Closing of the transactions contemplated
        by this Agreement will not be, a party to any agreement or arrangement, whether written or oral, with any of the other Investors or with any of the Company&#8217;s other shareholders or warrant holders, relating to the management of the Company,
        shareholder rights in the Company and/or the transfer of ADSs or other securities in the Company, including any voting agreements, shareholder agreements or any other similar agreement even if its title is different, or has any other arrangements
        or agreements with any of the Company&#8217;s shareholders, directors or officers.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">4. <u>Other Agreements</u>.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 72pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Governing Law; Specific Enforcement; Submission to Jurisdiction; Waiver of Jury Trial</u>.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Transaction Documents shall be governed by and construed in accordance with the internal laws of the
        State of New York applicable to agreements made and to be performed entirely within such state, without regard to the conflicts of law principles of such state.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The parties hereto acknowledge and agree that irreparable damage would occur in the event that any of the
        provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.&#160; It is accordingly agreed that the parties hereto shall be entitled to an injunction or injunctions, specific performance or other
        equitable relief to prevent breaches or threatened breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in the courts described in this Section 4.1, without proof of damages or otherwise (in each case,
        subject to the terms and conditions of this Section 4.1) (and each party hereto acknowledges and agrees that any party seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions
        of this Agreement in accordance with this Section 4.1 shall not be required to provide any bond or other security in connection with any such order or injunction), this being in addition to any other remedy to which they are entitled at law or in
        equity.&#160; The parties hereto agree not to assert that a remedy of specific enforcement is unenforceable, invalid, contrary to applicable law or inequitable for any reason, or that a remedy of monetary damages would provide an adequate remedy or that
        the parties otherwise have an adequate remedy at law.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each of the parties hereto irrevocably and unconditionally submits to the exclusive jurisdiction of the
        Supreme Court of the State of New York, New York County, and the United States District Court for the Southern District of New York, for the purposes of any demand, action, suit, countersuit, arbitration, inquiry, proceeding or investigation by or
        before any governmental entity or any arbitration or mediation tribunal (&#8220;<u>Action</u>&#8221;) or other proceeding arising out of this Agreement and the rights and obligations arising hereunder, and irrevocably and unconditionally waives any objection
        to the laying of venue of any such Action or proceeding in any such court, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Action or proceeding has been brought in an inconvenient
        forum.&#160; Each party hereto agrees that service of any process, summons, notice or document by registered mail to such party&#8217;s respective address set forth on the signature pages attached hereto shall be effective service of process for any such
        Action or proceeding.</font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 144pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO
        A TRIAL BY JURY IN RESPECT OF ANY ACTION, CLAIM OR OTHER PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT. EACH PARTY HERETO (i) CERTIFIES THAT NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED,
        EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF ANY ACTION, CLAIM OR OTHER PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVER, (iii) IT MAKES SUCH WAIVER
        VOLUNTARILY AND (iv) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 4.1.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Counterparts</u>.&#160; This Agreement may be executed in two (2) or more counterparts, each of which shall be
        deemed an original, but all of which together shall constitute one (1) and the same instrument. In the event that any signature is delivered by e-mail delivery of a &#8220;.pdf&#8221; format data file, such signature shall create a valid and binding obligation
        of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such &#8220;.pdf&#8221; signature page were an original thereof.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Titles and Subtitles</u>.&#160; The titles and subtitles used in this Agreement are used for convenience only
        and are not to be considered in construing or interpreting this Agreement.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notices</u>.&#160; All notices and other communications given or made pursuant hereto shall be in writing and
        shall be deemed effectively given: (a)&#160;upon personal delivery to the party to be notified, (b)&#160;when sent by e-mail or facsimile, (c)&#160;five (5)&#160;days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or
        (d)&#160;one (1)&#160;day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.&#160; All communications shall be sent to the respective parties at the addresses set forth on the
        signature pages attached hereto (or at such other addresses as shall be specified by notice given in accordance with this Section&#160;4.4).</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">4.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Severability</u>.&#160; If one or more provisions of this Agreement are held to be unenforceable under
        applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">4.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Aggregation of Shares</u>.&#160; All Shares held or acquired by affiliated entities or persons shall be
        aggregated together for the purpose of determining the availability of any rights under this Agreement.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">4.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Entire Agreement</u>.&#160; The Transaction Documents, together with the exhibits and schedules thereto, the
        Prospectus and the Prospectus Supplement, constitute the entire understanding among the parties and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth
        herein or therein.</font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-indent: 72pt;">4.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Amendments; Waivers</u>. No provision of this Agreement may be waived, modified, supplemented or amended except in a
      written instrument signed, in the case of an amendment, by the Company and the Investor which purchased at least 50.1% in interest of the Shares and Pre-Funded Warrants based on the initial subscription amounts hereunder (or, prior to the Closing,
      the Company and each Investor) or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts an Investor (or
      group of Investors), the consent of at least 50.1% in interest of the Shares and Pre-Funded Warrants (based on the initial subscription amounts hereunder) of such disproportionately impacted Investor (or group of Investors) shall also be required. No
      waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
      hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and
      obligations of the Investor relative to the comparable rights and obligations of the other Investors shall require the prior written consent of such adversely affected Investor. Any amendment effected in accordance with this Section 4.8 shall be
      binding upon each Investor and holder of Securities and the Company.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; text-indent: 72pt;"><font style="font-family: 'Times New Roman',Times,serif;">4.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Successors and Assigns</u>.&#160; This Agreement shall be binding upon and inure to the benefit of the parties
        and their successors and permitted assigns.&#160; The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor (other than by merger).&#160; The Investor may assign any or all of its
        rights under this Agreement to any person to whom the Investor assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction
        Documents that apply to the &#8220;Investor&#8221;.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; text-indent: 72pt;"><font style="font-family: 'Times New Roman',Times,serif;">4.10&#160;&#160;&#160;&#160;&#160;&#160; <u>Further Assurances</u>. Each of the Company and the Investors shall use its respective commercially
        reasonable efforts to take, or cause to be taken, all actions to assist and cooperate with the other parties hereto in doing all necessary items to consummate the transactions hereby contemplated.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; text-indent: 72pt;"><font style="font-family: 'Times New Roman',Times,serif;">4.11&#160;&#160;&#160;&#160;&#160; &#160; <u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken
        together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart.&#160; In the
        event that any signature is delivered by e-mail delivery (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law,
        e.g., www.docusign.com) or other transmission method, such signature shall be deemed to have been duly and validly delivered and shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with
        the same force and effect as if such &#8220;.pdf&#8221; signature page were an original thereof.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
      signatories as of the date first indicated above.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z934fae9527f74f7a8a5487b2b27aef77" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 60%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">REDHILL BIOPHARMA LTD.</div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
          <td style="width: 40%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;"><u>Address for Notice:</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">By:__________________________________________</div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;Name:</div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;Title:</div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
          <td style="width: 40%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Fax: +972-3-5413144</div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br>
            </div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">[PURCHASER SIGNATURE PAGES TO RDHL SECURITIES PURCHASE AGREEMENT]</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
      signatories as of the date first indicated above.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Name of Purchaser: Jason Greene</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">Signature of Authorized Signatory of Purchaser</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">: _________________________________</font></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Name of Authorized Signatory: Jason Greene</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Title of Authorized Signatory: N/A</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Email Address of Authorized Signatory: _________________________________________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Address for Notice to Purchaser:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Address for Delivery of Warrants to Purchaser (if not same as address for notice):</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Subscription Amount:__________________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">ADSs: __________________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Pre-Funded Warrant ADSs: ____________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Ordinary Warrant ADSs: ________________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">EIN Number: ____________________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Ordinary Shares Currently Held:&#160; ____________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Warrants Currently Held: ___________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;">[Signature Pages Continue]</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>3
<FILENAME>exhibit_1-2.htm
<DESCRIPTION>EXHIBIT 1.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> </u>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 1.2</u><br>
    </div>
    <div style="text-align: center; text-indent: 360pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">DEPOSITARY SHARES</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">REDHILL BIOPHARMA LTD.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Number of American Depositary Shares: _________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <table cellspacing="0" cellpadding="0" border="0" id="z2f423e82f305459ebd67f4cb678b67c1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 80%;">
              <div>&#160;</div>
            </td>
            <td style="width: 20%;">
              <div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Issue Date: ___, 2024</div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Initial Exercise Date: ___, 2024</div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value
      received, ________ or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<u>Initial Exercise Date</u>&#8221;) and
      on or prior to 5:00 p.m. (New York City time) on _____<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> (the &#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from RedHill Biopharma Ltd., a company organized under the laws of the State of Israel (the &#8220;<u>Company</u>&#8221;),
      up to _________ Ordinary Shares, par value NIS 0.01 per share, of the Company (the &#8220;<u>Warrant Shares</u>&#8221;) represented by _____ American Depositary Shares (each, an &#8220;<u>ADS</u>&#8221; and, collectively, the &#8220;<u>ADSs</u>&#8221; and the ADSs issuable upon
      exercise of this Warrant, the &#8220;<u>Warrant ADSs</u>&#8221;), as subject to adjustment hereunder. The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b).</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Section 1</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Definitions</u>.&#160; Capitalized terms used and not otherwise defined herein shall have the
        meanings set forth in that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated ___, 2024, among the Company and the purchasers signatory thereto.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Section 2</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise</u>.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise of Warrant</u>.&#160; Exercise of the purchase rights represented by this Warrant
        may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment)
        of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;).&#160; Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i)
        herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price (as defined in Section 2(b) herein) for the Warrant ADSs specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check
        drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<font style="font-weight: bold;">&#160; </font>No ink-original Notice of Exercise shall be required,
        nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.&#160; Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the
        Company until the Holder has purchased all of the Warrant ADSs available hereunder and the Warrant has been exercised in full, in which case, the Holder shall, upon request of the Company, surrender this Warrant to the Company for cancellation
        within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant ADSs available hereunder shall have
        the effect of lowering the outstanding number of Warrant ADSs purchasable hereunder in an amount equal to the applicable number of Warrant ADSs purchased.&#160; The Holder and the Company shall maintain records showing the number of Warrant ADSs
        purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice.&#160; <font style="font-weight: bold;">The Holder and any assignee, by acceptance of this
          Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant ADSs hereunder, the number of Warrant ADSs available for purchase hereunder at any given time may be less than
          the amount stated on the face hereof.</font></font></div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;"> </font><br>
      </font>
      <hr noshade="noshade" align="left" style="text-align: left; background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> Insert the date that is the five (5) year anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day, insert the immediately
        following Trading Day.</div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Exercise Price</u>.&#160; The exercise price per ADS under this Warrant shall be <font style="font-weight: bold;">$0.75</font>, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective
        registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant ADSs by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless
        exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant ADSs equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: -31.5pt; margin-left: 103.5pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of
      Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of
      &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the
      applicable Notice of Exercise or (z) the Bid Price of the ADSs on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during
      &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the
      applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: -36pt; margin-left: 108pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: -31.5pt; margin-left: 103.5pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(X) = the number of Warrant ADSs that would be issuable upon exercise of this Warrant in accordance with the
      terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<u>Bid Price</u>&#8221;
        means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs are then listed or quoted on a Trading Market, the bid price of the ADSs for the time in question (or the nearest preceding date) on the
        Trading Market on which the ADSs are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Best Market (the &#8220;<u>OTCQB</u>&#8221;) or OTCQX
        Venture Market (&#8220;<u>OTCQX</u>&#8221;) is not a Trading Market, the volume weighted average price of the ADSs for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not then listed or quoted for trading on OTCQB
        or OTCQX and if prices for the ADSs are then reported on the Pink Open Market (the &#8220;<u>Pink Market</u>&#8221;) operated by the OTC Markets Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid
        price per share of the ADSs so reported, or (d) in all other cases, the fair market value of an ADS as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and
        reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<u>VWAP</u>&#8221;
        means, for any date, the price determined by the first of the following clauses that applies: (a) if the ADSs are then listed or quoted on a Trading Market, the daily volume weighted average price of the ADSs for such date (or the nearest preceding
        date) on the Trading Market on which the ADSs are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the
        volume weighted average price of the ADSs for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the ADSs are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the ADSs are then reported on the
        Pink Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per ADS so reported, or (d) in all other cases, the fair market value of an ADS as determined by an independent appraiser
        selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">If Warrant ADSs are issued in such a cashless exercise, the parties acknowledge and agree that
      in accordance with Section 3(a)(9) of the Securities Act, the Warrant ADSs shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c).</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Mechanics of Exercise</u>.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Delivery of Warrant ADSs Upon Exercise</u>.&#160; The Company shall cause its registrar to
        deposit the Warrant Shares subject to such exercise with the Israeli custodian of the Depositary, and cause the Depositary to credit the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit
        or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant ADSs to or resale of the Warrant ADSs by the
        Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant ADSs to which
        the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (A) the earlier of (i) two (2) Trading Days and (ii) the number of days comprising the Standard
        Settlement Period, in each case after the delivery to the Company of the Notice of Exercise and (B) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company (such date, the &#8220;<u>Warrant ADS Delivery Date</u>&#8221;). Upon delivery
        of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant ADSs with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
        ADSs, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant ADS Delivery Date.&#160; If the Company fails for any reason to deliver to the Holder the Warrant ADSs subject to a
        Notice of Exercise by the Warrant ADS Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant ADSs subject to such exercise (based on the VWAP of an ADS on the date of the
        applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after the Warrant ADS Delivery Date) for each Trading Day after such Warrant ADS Delivery Date until such Warrant ADSs are delivered or
        Holder rescinds such exercise. The Company agrees to maintain a depositary that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard
        settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the ADSs as in effect on the date of delivery of the Notice of Exercise.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Delivery of New Warrants Upon Exercise</u>.&#160; If this Warrant shall have been exercised
        in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased
        Warrant ADSs called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">iii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Rescission Rights</u>.&#160; If the Company fails to cause the Depositary to transmit to
        the Holder the Warrant ADSs pursuant to Section 2(d)(i) by the Warrant ADS Delivery Date, then the Holder will have the right to rescind such exercise.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">iv.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant ADSs Upon Exercise</u>.&#160;
        In addition to any other rights available to the Holder, if the Company fails to cause the Depositary to deliver to the Holder the Warrant ADSs in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the
        Warrant ADS Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, ADSs to deliver in satisfaction of a sale by the
        Holder of the Warrant ADSs which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage
        commissions, if any) for the ADSs so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant ADSs that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at
        which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant ADSs for which such exercise was not honored (in which case
        such exercise shall be deemed rescinded) or deliver to the Holder the number of ADSs that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.&#160; For example, if the Holder purchases ADSs having
        a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of ADSs with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
        shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.&#160; Nothing
        herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely
        deliver ADSs upon exercise of the Warrant as required pursuant to the terms hereof.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">v.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Fractional Shares or Scrip</u>.&#160; No fractional Warrant ADSs shall be issued upon the
        exercise of this Warrant.&#160; As to any fraction of an ADS which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount
        equal to such fraction multiplied by the Exercise Price or round up to the next whole ADS; provided, however the fraction of an ADS shall not be rounded up to the next whole ADS if such rounding results in the issue price being lower than the par
        value of the Ordinary Shares.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">vi.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Charges, Taxes and Expenses</u>.&#160; Issuance of Warrant ADSs shall be made without
        charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant ADSs, all of which taxes and expenses shall be paid by the Company, and such Warrant ADSs shall be issued in the name of the
        Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant ADSs are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall
        be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.&#160; The Company shall pay
        all Depositary fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the
        Warrant&#160; ADSs, if any. The Company shall pay all applicable fees and expenses of the Depositary in connection with the issuance of the Warrants hereunder.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">vii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Closing of Books</u>.&#160; The Company will not close its shareholder books or records in
        any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Beneficial Ownership</u>. The number of Ordinary Shares beneficially owned by the Holder
        and its Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, the &#8220;Attribution Parties&#8221;) Attribution Parties shall include the number of Ordinary Shares underlying ADSs held by
        the Holder and its Attribution Parties plus the number of Ordinary Shares underlying such Warrant ADSs issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Ordinary Shares
        underlying such Warrant ADSs which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the
        unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Ordinary Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
        beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&#160; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the
        Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder
        is solely responsible for any schedules required to be filed in accordance therewith.&#160;&#160; To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
        securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
        the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, and the Company shall
        have no obligation to verify or confirm the accuracy of such determination.&#160;&#160; In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and
        regulations promulgated thereunder.&#160; For purposes of this Section 2(e), in determining the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding Ordinary Shares as reflected in (A) the Company&#8217;s most recent Annual
        Report on Form 20-F, Report on Form 6-K or other public filing filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the depositary setting forth
        the number of Ordinary Shares outstanding.&#160; Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of Ordinary Shares then outstanding.&#160; In any case, the
        number of outstanding Ordinary Shares shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such
        number of outstanding Ordinary Shares was reported.&#160; The provisions contained in this paragraph shall apply to a successor holder of this Warrant.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Section 3</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Certain Adjustments</u>.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Share Dividends and Splits</u>. If the Company, at any time while this Warrant is
        outstanding: (i) pays a share dividend or otherwise makes a distribution or distributions on its Ordinary Shares or ADSs or any other equity or equity equivalent securities payable in Ordinary Shares or ADSs (which, for avoidance of doubt, shall
        not include any ADSs issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding Ordinary Shares or ADSs into a larger number of Ordinary Shares or ADSs, as applicable, (iii) combines (including by way of reverse share split)
        outstanding Ordinary Shares or ADSs into a smaller number of Ordinary Shares or ADSs, as applicable, or (iv) issues by reclassification Ordinary Shares, ADSs or any capital share of the Company, as applicable, then in each case the Exercise Price
        shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares or ADSs, as applicable (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of
        Ordinary Shares or ADSs, as applicable outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain
        unchanged.&#160; Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately
        after the effective date in the case of a subdivision, combination or re&#8209;classification.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">b)&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <u>Reserved</u>.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Reserved.</u></font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);">d)</font><font style="font-family: 'Times New Roman',Times,serif;"><font style="color: rgb(0, 0, 0);">&#160;&#160;</font>&#160;&#160;&#160;&#160; &#160; &#160; <u>Reserved.</u></font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the
        Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license,
        assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or
        another Person) is completed pursuant to which holders of Ordinary Shares (including any Ordinary Shares underlying ADSs) are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the
        holders of 50% or more of the outstanding Ordinary Shares (including any Ordinary Shares underlying ADSs), (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or
        recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or
        more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of
        Persons whereby such other Person or group acquires more than 50% of the outstanding Ordinary Shares (including any Ordinary Shares underlying ADSs) (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the
        Holder shall have the right to receive, for each Warrant Share represented by each Warrant ADSs that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder
        (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of&#160; common or ordinary shares of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
        consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of Ordinary Shares (including any Ordinary Shares underlying ADSs) equal to the amount of Warrant Shares
        represented by the Warrant ADSs for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).&#160; For purposes of any such exercise, the
        determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Ordinary Share or ADS, as applicable, in such Fundamental
        Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.&#160; If holders of Ordinary Shares or
        ADSs are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following
        such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this
        Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
        prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to
        this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Ordinary Shares or ADSs acquirable and receivable upon exercise of this Warrant (without
        regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of
        the Ordinary Shares or ADSs pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this
        Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed
        to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the
        Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">6</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest
        cent or the nearest 1/100th of an ADS, as the case may be. For purposes of this Section 3, the number of Ordinary Shares or ADSs deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares or ADSs, as
        applicable, (excluding treasury shares, if any) issued and outstanding.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notice to Holder</u>.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">i.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to
        any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant ADSs and setting forth a
        brief statement of the facts requiring such adjustment.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">ii.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend
        (or any other distribution in whatever form) on the Ordinary Shares or ADSs, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares or ADSs, (C) the Company shall authorize the granting to all
        holders of the Ordinary Shares or ADSs rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any
        reclassification of the Ordinary Shares or ADSs, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Ordinary
        Shares or ADSs are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause
        to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
        specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Ordinary Shares or
        ADSs of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become
        effective or close, and the date as of which it is expected that holders of the Ordinary Shares or ADSs of record shall be entitled to exchange their shares of the Ordinary Shares or ADSs for securities, cash or other property deliverable upon such
        reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be
        specified in such notice.&#160; To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Company&#8217;s subsidiaries, the Company shall simultaneously file such
        notice with the Commission pursuant to a Report on Form 6-K.&#160; The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may
        otherwise be expressly set forth herein.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Section 4</u>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Transfer of Warrant</u>.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Transferability</u>. This Warrant and all rights hereunder are transferable, in whole or
        in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or
        attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.&#160; Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
        assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be
        cancelled.&#160; Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this
        Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full.&#160; The Warrant, if properly assigned in accordance herewith, may be exercised by a new
        holder for the purchase of Warrant ADSs without having a new Warrant issued.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">7</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon
        presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.&#160; Subject to compliance with
        Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such
        notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant ADSs issuable pursuant thereto.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be
        maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time.&#160; The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the
        purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Section 5</u>.&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160; <u>Miscellaneous</u>.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No Rights as Shareholder Until Exercise; No Settlement in Cash</u>.&#160; This Warrant does
        not entitle the Holder to any voting rights, dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.&#160; Without limiting the rights of a
        Holder to receive Warrant ADSs on a &#8220;cashless exercise,&#8221; and to receive the cash payments contemplated pursuant to Sections 2(d)(i) and 2(d)(iv), in no event will the Company be required to net cash settle an exercise of this Warrant.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">b)&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon
        receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant ADSs, and in case of loss, theft or destruction, of indemnity or
        security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new
        Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</font></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">8</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Saturdays, Sundays, Holidays, etc</u>.&#160; If the last or appointed day for the taking of
        any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">d)&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <u>Authorized Shares</u>.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; margin-left: 72pt; text-indent: 36pt;">The Company covenants that, at all times during the period the Warrant is outstanding, it will reserve from
      its authorized and unissued Ordinary Shares a sufficient number of shares to provide for the issuance of the Warrant ADSs and underlying Ordinary Shares upon the exercise of any purchase rights under this Warrant.&#160; The Company further covenants that
      its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.&#160; The Company will take all such reasonable
      action as may be necessary to assure that such Warrant ADSs and Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Ordinary Shares or ADSs
      may be listed.&#160; The Company covenants that all Warrant ADSs which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
      ADSs in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring
      contemporaneously with such issue).</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including,
      without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
      performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in
      this Warrant against impairment.&#160; Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant ADSs above the amount payable therefor upon such exercise immediately prior to such increase in par
      value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant ADSs upon the exercise of this Warrant and (iii) use commercially reasonable efforts to
      obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Before taking any action which would result in an adjustment in the number of Warrant ADSs for which this Warrant is
      exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">9</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and
        interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Restrictions</u>.&#160; The Holder acknowledges that the Warrant ADSs acquired upon the
        exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Nonwaiver and Expenses</u>.&#160; No course of dealing or any delay or failure to exercise
        any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies, notwithstanding the fact that the right to exercise this Warrant terminates on the Termination Date.&#160;
        Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to
        the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto
        or in otherwise enforcing any of its rights, powers or remedies hereunder.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Notices</u>.&#160; Any notice, request or other document required or permitted to be given or
        delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Limitation of Liability</u>.&#160; No provision hereof, in the absence of any affirmative
        action by the Holder to exercise this Warrant to purchase Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Ordinary Shares or ADSs or as
        a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Remedies</u>.&#160; The Holder, in addition to being entitled to exercise all rights granted
        by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant.&#160; The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the
        provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Successors and Assigns</u>.&#160; Subject to applicable securities laws, this Warrant and the
        rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.&#160; The provisions of this Warrant are intended to be for
        the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant ADSs.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Amendment</u>.&#160; This Warrant may be modified or amended or the provisions hereof waived
        with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Severability</u>.&#160; Wherever possible, each provision of this Warrant shall be
        interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or
        invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Headings</u>.&#160; The headings used in this Warrant are for the convenience of reference
        only and shall not, for any purpose, be deemed a part of this Warrant.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">********************</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;">(Signature Page Follows)</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">10</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <font style="font-family: 'Times New Roman',Times,serif;"></font><br>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
      above indicated.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z1a079d13ce92417389bcd2ae0b060734">

        <tr>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">REDHILL BIOPHARMA LTD.</div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">By: __________________________________________</div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;Name:</div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;Title:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">11</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">NOTICE OF EXERCISE</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">TO:&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">REDHILL BIOPHARMA LTD.</font></font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">THE BANK OF NEW YORK MELLON</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 13.5pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned hereby elects to purchase ________ Warrant ADSs of the Company pursuant
        to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 13.5pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Payment shall take the form of (check applicable box):</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#9744; in lawful money of the United States; or</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#9744; if permitted the cancellation of such number of Warrant ADSs as is necessary, in accordance with the formula set forth in subsection
      2(c), to exercise this Warrant with respect to the maximum number of Warrant ADSs purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 13.5pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Please register and issue said Warrant ADSs in the name of the undersigned or in such
        other name as is specified below:</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">_______________________________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 108pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">_______________________________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The Warrant ADSs shall be delivered to the following DWAC Account Number:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 108pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">_______________________________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 108pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">_______________________________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 108pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">_______________________________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">[SIGNATURE OF HOLDER]</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Name of Investing Entity: ________________________________________________________________________</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">Signature of Authorized Signatory of Investing
        Entity</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">: _________________________________________________</font></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Name of Authorized Signatory: ___________________________________________________________________</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Title of Authorized Signatory: ____________________________________________________________________</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Date: ________________________________________________________________________________________</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">EXHIBIT B</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">ASSIGNMENT FORM</div>
    <div style="text-align: center; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 10.5pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: italic;">&#160;(To assign the foregoing Warrant, execute this form and supply required information.&#160; Do not
      use this form to exercise the Warrant to purchase Warrant ADSs.)</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 10.5pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8ba74394f747448bbe2685725a19f291">

        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">Name:</div>
          </td>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">______________________________________</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">(Please Print)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">Address:</div>
          </td>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">______________________________________</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Phone Number:</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Email Address:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">(Please Print)</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">______________________________________</div>
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">______________________________________</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">Dated: _______________ __, ______</div>
          </td>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);">Holder&#8217;s Signature:</font> <font style="font-family: 'Times New Roman',Times,serif;">______________________________________&#160;&#160;
                <br>
              </font></div>
          </td>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0);">Holder&#8217;s Address:</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;
                ______________________________________&#160;&#160;&#160;&#160;&#160; <br>
              </font></div>
          </td>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>exhibit_5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25; text-align: right;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-family: 'Times New Roman',Times,serif;"><u><font style="font-weight: bold;">Exhibit 5.1</font></u><br style="line-height: 1.25;">
        </font></div>
      <div style="line-height: 1.25; text-align: right;"><font style="font-family: 'Times New Roman',Times,serif;"><u><font style="font-weight: bold;"> <br>
            </font></u></font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zdbc3777fa7a34599a2f21a58a86704c2">

            <tr>
              <td style="width: 50.00%;">
                <div>&#160;<img src="image00001.jpg"></div>
              </td>
              <td style="width: 50.00%;">
                <div style="text-align: right;"><br>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    </div>
    <div style="text-align: right; line-height: 1.25;">April 3, 2024</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">RedHill Biopharma Ltd.</div>
    <div style="text-align: justify; line-height: 1.25;">21 Ha&#8217;arba&#8217;a Street</div>
    <div style="text-align: justify; line-height: 1.25;">Tel Aviv, 6473921</div>
    <div style="text-align: justify; line-height: 1.25;">Israel</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Ladies and Gentlemen:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have acted as Israeli counsel to RedHill Biopharma Ltd., (the &#8220;Company&#8221;), an Israeli company, in connection with
      the issue and sale by the Company of (i) 2,144,487 American Depositary Shares (the &#8220;<font style="font-weight: bold;">Offering ADSs</font>&#8221;), each representing 400 ordinary shares, NIS
      0.01 par value per share of the Company (the &#8220;<font style="font-weight: bold;">ADSs</font>&#8221;) and (ii) Warrants (the &#8220;<font style="font-weight: bold;">Warrants</font>&#8221;) to acquire up to 2,144,487 ADSs, all pursuant to the terms of the Securities Purchase Agreement dated March 28, 2024 (the &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;) by and between the Company and each of the purchasers identified on the signature pages thereto (collectively, the &#8220;<font style="font-weight: bold;">Purchasers</font>&#8221;). The Offering ADSs and the Warrants are being issued pursuant to registration statement on Form F-3 (File No. 333-258259) (the <font style="font-weight: bold;">&#8220;Registration Statement&#8221;) </font>filed with the Securities and Exchange Commission (the <font style="font-weight: bold;">&#8220;Commission&#8221;) </font>under the Securities Act of 1933,
      as amended (the &#8220;<font style="font-weight: bold;">Securities</font>&#160;<font style="font-weight: bold;">Act</font>&#8221;), the
      related base prospectus which forms a part of the Registration Statement, and the prospectus supplement dated March 29, 2024 related to the c Offering ADSs and Warrants (the &#8220;<font style="font-weight: bold;">Prospectus Supplement</font>&#8221;).</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In connection with this opinion, we have examined and relied upon the Registration Statement, the Prospectus
      Supplement, the Company&#8217;s Amended and Restated Articles of Association, and such statutes, regulations, corporate records, documents, certificates and such other instruments that we have deemed relevant and necessary for the basis of our opinions
      hereinafter expressed. In such examination, we have assumed: (i)&#160;the authenticity of original documents and the genuineness of all signatures; (ii)&#160;the conformity to the originals of all documents submitted to us as copies; (iii)&#160;the truth, accuracy
      and completeness of the information, representations and warranties contained in the corporate records, documents, certificates and instruments we have reviewed; (iv)&#160;the due execution and delivery of all documents where due execution and delivery
      are a prerequisite to the effectiveness thereof; and (v)&#160;the legal capacity of all natural persons.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are members of the Israel Bar and we express no opinion as to any matter relating to the laws of any jurisdiction
      other than the laws of the State of Israel and have not, for the purpose of giving this opinion, made any investigation of the laws of any jurisdiction other than the State of Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On the basis of the foregoing, and in reliance thereon, we are of the opinion that the (i) Ordinary Shares underlying
      the Offering ADSs to be sold to the Purchasers as described in the Registration Statement and the Prospectus Supplement, have been duly authorized and have been, or upon delivery of the Offering ADSs and payment therefor in accordance with the
      Agreement, will be, validly issued, fully paid and non-assessable and (ii) Ordinary Shares issuable upon exercise of&#160; the Warrants have been duly authorized, and upon payment for the Warrants in accordance with the Agreement and the issuance and
      delivery of such Ordinary Shares by the Company upon exercise of the Warrants against receipt of the exercise price therefor in accordance with the terms of the Warrants, will be validly issued, fully paid and non-assessable.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We hereby consent to the filing of this opinion as an exhibit to the Company&#8217;s report on Form 6-K dated April 3, 2024
      which is incorporated by reference into the Registration Statement and to the use of our name wherever it appears in the Registration Statement and the Prospectus Supplement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In giving such consent, we do not believe that we are &#8220;experts&#8221; within the meaning of such term as used in the
      Securities Act, or the rules and regulations of the Commission issued thereunder with respect to any part of the Registration Statement, including this opinion as an exhibit or otherwise.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zce38dc06a2574bb8948da33319c91551" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Very truly yours,</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">/s/ Goldfarb Gross Seligman &amp; Co.</div>
            <div style="line-height: 1.25;">Goldfarb Gross Seligman &amp; Co.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;"> <img src="image00003.jpg"></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
  </div>
  <div class="BRPFPageNumberArea" style="text-align: center;">
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>5
<FILENAME>exhibit_5-2.htm
<DESCRIPTION>EXHIBIT 5.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 24.3.1.5224
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <div class="BRPFPageHeader">
      <div style="text-align: justify; line-height: 1.25;">
        <div style="text-align: right;">
          <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u><font style="font-weight: bold;">Exhibit 5.2</font></u><br>
        </div>
        <div style="text-align: right;"><u><font style="font-weight: bold;"> <br>
            </font></u></div>
        <div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zfc25ac67d0dd4a3c8299eb2d5f29d6ef">

              <tr>
                <td style="width: 50.00%;">
                  <div>&#160;<img width="212" height="18" src="image00004.jpg"></div>
                </td>
                <td style="width: 50.00%;">
                  <div style="text-align: right;">&#160;<img width="39" height="39" src="image00005.jpg"></div>
                </td>
              </tr>

          </table>
        </div>
        <div><br>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">RedHill Biopharma Ltd.</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">April 3, 2024</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">Page <font class="BRPFPageNumber">1</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">April 3, 2024</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">RedHill Biopharma Ltd.</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">21 Ha'arba'a Street</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">Tel Aviv, Israel 6473921</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">Ladies and Gentlemen:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">We have acted as special U.S. counsel to RedHill Biopharma Ltd., an Israeli company (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;), in connection with the offering by the Company of (i) 2,144,487 American Depositary Shares (the &#8220;<font style="font-weight: bold; font-style: italic;">ADSs</font>&#8221;), each ADS representing four hundred (400) ordinary shares of the Company, par value NIS 0.01 (the &#8220;<font style="font-weight: bold; font-style: italic;">Ordinary
        Shares</font>&#8221;) and (ii) warrants (the &#8220;<font style="font-weight: bold; font-style: italic;">Warrants</font>&#8221;) to purchase up to 2,144,487 ADSs (the &#8220;<font style="font-weight: bold; font-style: italic;">Warrant ADSs</font>&#8221;) at an exercise price of $0.75 per ADS, at a combined purchase price of $0.58289 per ADS and accompanying Warrant, pursuant to a registration statement on Form F-3
      (Registration Statement No. 333-258259) (the &#8220;<font style="font-weight: bold; font-style: italic;">Registration Statement</font>&#8221;) filed on July 29, 2021 with the Securities and Exchange Commission (the
      &#8220;<font style="font-weight: bold; font-style: italic;">Commission</font>&#8221;) under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Securities Act</font>&#8221;) and declared effective on August 9, 2021, the prospectus dated August 9, 2021 (the &#8220;<font style="font-weight: bold; font-style: italic;">Base
        Prospectus</font>&#8221;) and the prospectus supplement dated March 29, 2024, filed with the Commission pursuant to Rule 424(b) of the rules and regulations of the Securities Act (the &#8220;<font style="font-weight: bold; font-style: italic;">Prospectus Supplement</font>&#8221; and the Base Prospectus as supplemented by the Prospectus Supplement, the &#8220;<font style="font-weight: bold; font-style: italic;">Prospectus</font>&#8221;).
      This opinion is being rendered in connection with the offering by the Company of the ADSs, the Warrants and the Warrant ADSs pursuant to the terms of a Securities Purchase Agreement dated March 29, 2024, entered into between the Company and the
      purchasers identified on the signature pages thereto. The ADSs and the Warrant ADSs will be issued pursuant to a Deposit Agreement dated as of December 26, 2012 (the &#8220;<font style="font-weight: bold; font-style: italic;">Deposit Agreement</font>&#8221;) among the Company, The Bank of New York Mellon, as depositary (the &#8220;<font style="font-weight: bold; font-style: italic;">Depositary</font>&#8221;), and all
      Owners and Holders (each as defined therein) from time to time of ADSs of the Company issued thereunder.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">In connection with this opinion, we have examined such corporate records, documents, instruments, certificates of public officials and
      of the Company and such questions of law as we have deemed necessary for the purpose of rendering the opinions set forth herein.</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">In such examination, we have assumed the genuineness of all signatures and the authenticity of all items submitted to us as originals
      and the conformity with originals of all items submitted to us as copies.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">
      <div style="line-height: 1.25;">RedHill Biopharma Ltd.</div>
      <div style="line-height: 1.25;">April 3, 2024</div>
      <div style="line-height: 1.25;">Page 2</div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">Based on the foregoing, and subject to the further assumptions and qualifications set forth below, it is our opinion that:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z245868f50f984a91b71cbcdcdb42236e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',serif;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman',serif;">When the ADSs have been issued and delivered in accordance with and in the manner described in the Prospectus against payment in full of the consideration payable therefor, the ADSs
              will be valid and legally binding obligations of the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zc972eec7640a4534864a3999d6902b0c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',serif;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman',serif;">When the ADSs are issued in accordance with the Deposit Agreement against the deposit of duly authorized, validly issued, fully paid and non-assessable Ordinary Shares, such ADSs will
              be duly and validly issued under the Deposit Agreement and will entitle the holders thereof to the rights specified therein.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zd67acd4385c342d9a5818b27a2f00d77" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',serif;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman',serif;">When the Warrants have been issued and delivered in accordance with and in the manner described in the Prospectus against payment in full of the consideration payable therefor, the
              Warrants will constitute valid and legally binding obligations of the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zc3a80b29f23c4ef899d5aafd3f073d7f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman',serif;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman',serif;">When the Warrants have been duly executed by the Company and delivered to and paid for in accordance with and in the manner described in the Prospectus against payment in full of the
              consideration payable therefor, the Warrant ADSs will have been duly authorized, and if, as and when issued in accordance with the Deposit Agreement against the deposit of duly authorized, validly issued, fully paid and non-assessable
              Ordinary Shares, such Warrant ADSs will be duly and validly issued under the Deposit Agreement and will entitle the holders thereof to the rights specified therein.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">Please note that we are opining only as to the matters expressly set forth herein and that no opinion should be inferred as to any
      other matter. We are opining herein as to the laws of the State of New York as in effect on the date hereof, and we express no opinion with respect to any other laws, rules or regulations. This opinion is based upon currently existing laws, rules,
      regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein. In rendering the
      foregoing opinions, we have relied, for matters involving Israeli law, solely on the opinion of Goldfarb Gross Seligman &amp; Co., Israeli counsel to the Company.</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">This opinion is being rendered solely in connection with the registration of the offering and sale of the ADSs, the Warrants and the
      Warrant ADSs, pursuant to the registration requirements of the Securities Act.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">
      <div style="line-height: 1.25;">RedHill Biopharma Ltd.</div>
      <div style="line-height: 1.25;">April 3, 2024</div>
      <div style="line-height: 1.25;">Page 3</div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">We hereby consent to the use of this opinion as Exhibit 5.2 to the Company&#8217;s Report on Form 6-K to be filed with the Commission on or
      about April 3, 2024, which will be incorporated by reference in the Registration Statement, and to the reference to us under the caption &#8220;Legal Matters&#8221; in the Prospectus Supplement forming part of the Registration Statement. In giving such consent,
      we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Securities Act or the rules or regulations of the Commission thereunder.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">Very truly yours,</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">/s/ Haynes and Boone, LLP</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',serif;">Haynes and Boone, LLP</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !W (<# 2(  A$! Q$!_\0
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M)B@W%C\^\ARPQQ@=.M#4NXW"JM;GN.E:_/=WT<+I'M8]5!_QKI:X+PZH768
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*%%%,L**** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !9 V4# 2(  A$! Q$!_\0
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M/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\
MLZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:
M!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11
M<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8
M/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\
MLZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:
M!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11
M<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8
M/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\
MLZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:
M!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11
M<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8
M/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\
MLZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:
M!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11
M<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8
M/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\
MLZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:
M!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11
M<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8
M/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\
MLZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:
M!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11
M<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8
M/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\
MLZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:
M!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11
M<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8
M/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\
MLZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:
M!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11
M<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8
M/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\
MLZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:
M!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11
M<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8
M/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\
MLZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:
M!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11
M<.==D>3?V[\8/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8
M/^A0T#_P._\ LZ/[=^,'_0H:!_X'?_9UZS11<.==D>3?V[\8/^A0T#_P._\
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M\4,4P+97;%NVX';[YS65JW@Z*^U*>^M-:US2Y;C!F6RN\1R$ #.QPP4X &5
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M>9V=YD965V<DLQRJ]2>F.E.X<Z-#0]+72-/6U2ZO;O#%C->3F:1B>N6/;V&
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MHGBN\DNK..[-I)=PC.8UE'*G)5NHR%(R,UF>*+;1[[PI=:<;+6K"]T[5]/\
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M,T#C'_$OM^/3]VM#0I121M4444B HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image00004.jpg
<TEXT>
begin 644 image00004.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  J >8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^?#_AX#^W
ME_T>S^US_P")(_&3_P";.O\ 4G_X)G^)?$7C+_@GE^Q+XL\7Z_K7BKQ5XE_9
M=^"6N>(O$WB35+[7/$&OZUJ?P_T*\U+6-:UG4Y[K4=5U34+N66ZOM0OKF>[N
M[B62>>:25V8_Y#]?ZXW_  2K_P"4:7[!7_9I/P$_]5OX>K]4\0</0HX/+W1H
M4:3EB:J;ITH0;7LEHW&*NO4_K_Z2>79?@LCX:E@\#@\)*>;8J,Y8;"T:$IQ6
M#349.E"#DD]4G=)GWU7\=O\ P=;_ +0?Q[^!>I_L*I\$OC=\7O@ZGB>Q_:3;
MQ*OPL^)7C/X>KXA;1KCX$#2&UQ?"6M:0-6;2AJFIC33?BX-B-1OQ:^5]KN/,
M_L2K^(__ (/"O^0K_P $^?\ L'_M2_\ I3^SS7R/!\(5.(\NA4A&I"7UN\)Q
M4XNV!Q35XR33LTFKK1I/='XMX)4*&*\3N&J&)H4L11FLYYZ->G"K2GRY!FDX
M\U.I&4)<LXQE&Z=I14EJDSRO_@UY_:A_:7^-?[?GQ>\*_&7]HCXZ?%OPQI_[
M'WC_ ,06'AOXF_%OQ_X]T&RUZU^-'[/^G6NMVFC^*O$&JZ?;:O;:?JNJ6%OJ
M4-NEY#9:E?VL<RP7EPDG]XE?YX__  :6?\I&OC3_ -F3_$;_ -7K^S?7^AQ7
M3QO3ITL^J0I4X4X?5L,^6G",(W<7=\L4E=]=#T_'W#8?">(>)HX7#T,-1659
M7)4L/2A1IIRI3NU"G&,4WU=KOJ%?S _\'/?[?FN?LU_LP^ /V9OA1XOU?PK\
M8/VD_$D>N:SKWA37)]%\2^#OA!\,=5TK6M0NK;5=$US3?$OAS4O''C@^&="T
M>]CM9]+\0>%]#^*&B7$T<D1CD_I\=UC1I)&5$16=W<A41%!9F9F("JH!+,2
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MQ_#I)T6U'BB7P3X@@T/5=9\7^._$,/\ /5_P3(_X+1_M-_LF_M<> /B#\?\
MX^?';XW? +7R_@/XQ^#/B+\5/B#\1+33?!?B.]L/M'C[POH?B;5O$5K%XS\
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M]M;V.G:=8V\%G8V<$-M;0Q01(B_L-_P0._X+L^*_ 7Q%MOV1/VZ/BEXP\;^
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MBN0\0_RN?^"AG[</[:GA/]OS]N/PKX5_:^_:B\,^&/#/[8/[3'A_PWX;\/\
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M:6?\I&OC3_V9/\1O_5Z_LWU_H<5Y''?_ "4%3_L%PW_I,CXGZ0O_ "<?%?\
M8IRK_P!,S/PE_P"#AK]N2#]CK_@GUXV\*>&M<M[#XS?M3G4?@5\.[.&]T]=:
ML/"VLZ<[?&+QS!ITFIV&LG3/#O@.XG\+1>(]"CO)O"WCWX@_#JZN8XX[R.2O
MF+_@V1_82T[X/?L(>+/CW\3?"=O=>*_VV+Z6YDT+Q1H]X\3?L^>$QKGA;P3H
MVK^'/$ND06\ECX^OM2\=>-S=67]I>'O'/P\\4?#V_,UU!!"L?\ZO_!>7]I'X
MF?\ !1C_ (*>:W\ ?@#X7\??%W1/V<4\0? CX5_#GX;>'?%_C77O%/C?PDFH
M>(?C]XNT/P+HMGJM_=ZJOB'1=7\/ZGJ_AW3Y;/5OA]\)O#'B.:1K&U>YC_1W
MP;_P5W_X.#?AYX/\*> / _\ P1[TWPOX+\#>&]"\'^$/#.C_ + W[<]GI'AW
MPOX9TNUT7P_H6E6D?Q4$=KIND:396FGV-M& D%K;Q1*-JBO5628NGPSA,#AI
MX6CB<SJPS#,/K.*I8>?L(ZX*ARU+2<?@JR5E[.M3G'=L^Q7 >=87PIR;A_*Z
M^4X#->*L71XDXD_M/-L+EE=8""C/), J>(E&K.GI0Q52+BOJV-P^(@_?FT?S
M=_\ !3C]C'6/V!_VV/C?^SG<6NH#P?H7B27Q-\(-7OVO;IO$7P;\8-)K?P\O
MSJ]YI>CQZWJFE:/<#PCXOU'3K,:6GCSPUXKTVRFG33S(?[@O^#9+]MZ7]I7]
MAJ?]GWQAJTE_\3_V.]4TSP"C7<MY<7FI_!3Q-%J.H_"#4)+FXABM /#BZ7XJ
M^&5II6G//_9'AOP%X6N+]HYM;@$G\I'_  5A^+7_  4X_;:C\&_M!_MG_P#!
M.WQ'^SM9_!'PY<^$-2^,?A[]E3]I'X3:-=>%O%7BC2D\,Z!\2/&7Q9USQ=HP
MTS1O&.K7EOX$MUO=#$6O_$#7;,'4KS7;.&#R?_@B5^W!%^PA_P % _A-\0_$
MVL0Z/\(?B5(_P1^-MS>3V=IING> ?'^H:9';>+=2O;[,.FZ=\/O&FG^%/'FL
MW\(%Z?#GA[7-+MG"ZK.DGT>:Y?B,YX6C"NZ-;,\%3C5YZ%6%=3Q&&BXU4JD&
MTYXG#MR<+K][.#:]V)^G\8<-YAQUX2PHX]X+&\5Y'A:>-57+L91S"%;,\LI.
M&*IPQ&'E)3JYKETIU/J_-%+%8G#RG']U!G^JK7Y3?\%A/^";7AS_ (*6?LEZ
M_P##>P@\/Z3\>OAZ]UXY_9X\>:OI\4DFB^,H(83JW@B_U:.:TU#3_!GQ4TNS
MC\+^)MMU<:9IFJ1^$_'U]H'B2_\  .BZ5+^K-%?CF%Q-;!XBCBL/-TZ^'J1J
MTYKI*+O9K:49:QG!WC.#<9)Q;1_$&49KC\CS/ YQEE>6&Q^78FGBL+6CKRU*
M4K\LXOW:E*I&].M1FG3K49SI5(RA.47_ (Q6EZE\4?V=?C%IVKV:Z]\,OC5\
M"OB7::C:)J&G"Q\3_#[XH_#'Q3'<P+?:1J]K(+/7O"?BS1%%SIVIV4@M]0L'
MMKVU8)+$?Z<O^"&?[$OQ._X*D_MO_$3_ (*6_MC._P 0?AS\/?B7<>+KZX\2
MSWTMM\5?VB=FG:SX1\(Z=I(#VL?PS^#&C3:%K4_AO^T+/0-)L[+X6?#G3_#V
MN^![OQ+I>B?B;_P5H_Y2;?MX?]G2_&/_ -3+5*_O"_X-H?\ E$I\&O\ LH?Q
MO_\ 5G:_7Z]Q/F=2GPYA<QHTJ=+%9G0PV%G5BG[2CA\;AI8JM3I5-)6;I*"O
MLI.:2G9G]L>+?%.*P/AGEO$N!PN'PN;\48/+,GJXVFG]:P&7YYEU7-<=A\+B
M$E5Y92P:HQYFE#VCKP4:T8R7[YT445^-'\+'^;I^R9_RL[:[_P!I&?VOO_4K
M^-M?V*_\%@O^"5'@/_@IY\ 'T.SGT;P7^TA\-;;4=8^ _P 4-1MI38PZC,B3
M:A\.O',ME#-J,GP\\;-;06M]>V<%]J7@S64T[QEI6EZZNFZKX2\4_P =7[)G
M_*SMKO\ VD9_:^_]2OXVU_I%U]WQ7BJ^"S3(\5AJCI5Z&2X"I3G'I)5<3HUM
M*,E>,X.\9P<HR3BVC^A?&#-\QR'BSP_SC*L3/"YA@.!>'\1AJ\->6<<5FB<9
MQ=XU*56#E2K49J5.M2G.E4C*$Y)_XRGBSPK\8?V9?C)JGA;Q+9^,/@]\<?@K
MXZ2*YCM[Z\\.^-/ /CWP=JL5Y8:GH^MZ/=QW-AJND:I:6FK^'_$>@ZB4<I8:
MWH6I2P26=Z_]S7P5_P""NF@_\%)/^",?[>_@KXFZMHFE_M@?!W]C3XTQ_%+P
MY EKI+?$?PO%\/\ 4],L/C9X4T:".WM/[.U2^N+73/'NEZ%$+'P=XQN[56T_
M0?#_ (O\$6EU[W_P7Y_X(QZ7^V[\/M4_:J_9X\-M;_M@?##PT!K.@Z-!*X_:
M)^'GAZWGF3PG=:7;[A/\5?#%IYI^'?B"S@.J>)-/C'PUU]=6M!X O? ?^=CH
M'B;Q'X4N[R_\,:]K'AV^U#0_$'AF_O-$U*\TNYO?#GBS1;[PWXHT&[GLIH)+
MC1_$7A[5-2T/7--F9[/5-)O[S3[V&:UN98G^NH2P'&F PN)7+0S++JU&I-*]
MZ%7GC.=-IW<\+BE2;I2NW&45JYTZD)?M&!GP[XZ<-Y5FJ]GE_$_#6.P6(K**
M<IY?C(5:5:OAY1;=2ME&;0PTI8:?,YTYTXOFE7PF(HS_ +//^#/+_CZ_X*&_
M]>_[*/\ Z,_:1K]N/^#BK_E#A^V%_P!V^_\ K4OP1K\1_P#@SR_X^O\ @H;_
M ->_[*/_ *,_:1K]N/\ @XJ_Y0X?MA?]V^_^M2_!&ODLX_Y+^C_V-,C_ /3>
M7GXSQK_RD=@_^RMX!_\ 47AP_P RSX5WOCW3?B?\.-1^%:7<GQ/T_P >^#[W
MX<1Z?I]EJU_)X\M?$.G3^$$LM+U*VO-.U*[;Q#'IRVVGW]G=65Y,4M[JVG@D
MDB;^I_\ X:;_ .#M?_H6_P!H3_Q$C]F'_P"<O7\V?[&__)WG[*W_ &<A\#O_
M %9WA>O]C"OHN-,V678G P>693C_ &M"K+GS'!_69T^6I%<M)\\.6+WDM;NS
M/U#QSXRI<+YED%&IPGPCQ&\7@<955;B3*(YE6PWL\13A[/"SE4A[*G4YN:I&
MSYI)/H?QH?L(?M _\'*'B/\ ;!_9\T+]K+0?C=;_ +.&J_$33++XOSZ[^S-\
M ?"VC1>$)H;I;I]2\1>%?A3I'B'1K07/V7S;_2]3L9X%^9KF.+S#7]E]%%?F
M.8X_^T:T*RP6 P/)25+V67X?ZM1E:<Y^TE#FG>J^?E<[ZPC!6]V[_D[BGB.G
MQ-CJ&-I\/\/\.JAA8X5X3AS+UEN#K.-:M5^LUJ,9SY\3+VOLI5;ZTJ5*%O<N
M_%_VBO@#\,_VIO@=\3_V>OC%H<?B#X<?%CPGJ'A3Q)9F&PEO;-;D)<:5XBT*
M74['4K/3O%?A+6[;3?%7@_6WL+F70/%6C:/K=K']KT^ C_-:_;X_X(*?MX_L
M2>)-9O\ 0_AQXA_:5^!R7-_-H/QB^"GAG5O$TUOHMN=0N4F^)'P[T@:OXN^'
M%_9Z39Q7NN7UW;ZO\/[.>\AT_2_B!K=TLR1?Z7'QH^./P@_9T^'VJ_%7XY_$
M7PI\+/AUHEQIMGJGB_QEJL&D:-:WFL7\&F:79^?,=TUW?WUS#!;6MNDL\A+.
M(_*BE=/4HY8YHXYH9$EBE19(I8V5XY(W4,DD;J2KHZD,K*2K*002#7H9)Q!F
M.0N4\.HU<+7E:I0K*7L9U*:C>5.::<*T83BI.+:<90]I"25.WTG /B3Q+X>2
MJU<NI4\7E&8UG]8P&.IU?J=?$X>%-3JX6O3<94,92I5J,:TJ<IQE2GA_K-&H
MHX=P_P 4,,5(92592"K D$$'(((Y!!Y!'(-?KY^RS_P78_X*;_LJZS9SZ1^T
MEXL^-/A!-1%]JOPZ_:0OM1^,WA[6(DTUM-ATR/Q%XFU!_B9X3TJU40WMOIW@
M'Q[X3LVU&VCGNX+N&:_MKS_2$_:/_8 _8J_:YAU4_M&?LQ_!_P"*&LZSI%IH
M%UXXU;PAI^F?%&VT:QO)+^ST[1?BUX=71OB;X=MK>[GN98D\/^+=,V_:[V//
ME7ETDW\.'_!??_@BA\)/^"=_ASP'^TQ^S1XE\06_P5^)?Q.N/AEKWPG\;:M)
MXAU7X>^--=T?Q=XY\*IX#\2R6BZMK7P_?PUX2U_1YK+QK?:MXPT&^T72[N[\
M7>,_^$IN1X8_0\!Q1DO$=6GEV89=R5J_-"E"O&GBJ+DU=QA7485*=1J-XR5*
M%FE::ERG]+<.^+7 GB=BL+PSQ%PS[#'8_P!K1PE#,J.%S;+Y594^>5+#X[V5
M'$X;$S5.]*K]3P_OTX.->%7V:/[ ?^"4W_!5+X3_ /!4OX->)?''A#PQJ/PS
M^)_PQU;2= ^+OPHU;5K37W\.W6OV5S?>&O$GAWQ!:06+:_X*\4IIVMV>D:CJ
M.C>'M8BUGPUXDTV\T1+6PT[6-:_4VO\ .\_X-.M5UZU_X*,?%32=.DN7T75?
MV1OB!/XBM%GF%DL>F?%3X+-I>J36JR""6[L[^[73K.YEC>6V@UK4(8&C6\GW
M_P"B'7YWQ-EE'*,WKX3#.7U?EI5J49-RE3C5C=TW)ZR49*2C)MRY.7F;E=O^
M9_%?A/ <&<:9AD^5N?\ 9SHX3&X.E5G*K4PU+%TE*6&E5FY3JJE5C45.<VZC
MHNFJDIS4IR****\ _-S_ "%_^"EG_*1K]O[_ +/8_:J_]7KX\K]/_P!@#_@N
M)_P4"_9Q_9U^&G[$O['7[.?PS^*,_@D>/M0MKV?X:?%OXL_$S59?&GCO6?&4
MU[I_A_P'XUT*PLX-(N_$DFFHMSX?UR*X46DDSQ2.T4GY@?\ !2S_ )2-?M_?
M]GL?M5?^KU\>5_H+_P#!MV /^"07[-9  +>(?CRS$#!8_P#"^OB.N6]3M55R
M><*!T K]JXCQ>%P?#^65<5E]+,8NI@X4Z-:K.E3A5E@:[5:2@FZG+!3@J;LK
MU.?F4H1/[P\3<YRG(_#7A;&YQPWA>)Z,L1D=##8'&XNMA<-0QD\AQ\H8VHJ-
M.H\2J5&G7HK#2Y(R>(]K[2,Z,+_QX?MQ_M._\%O_ (Z?#:XTS_@H7I7[8_PL
M_92U'Q/8:EXOB7]DVZ^$O@#3X+G7]V@:)KT=KX3^$=GXUM],UNVT^7PKX5^*
MGQ"N6EU2QT/7%NYM9AT[5W^[O^"&M]_P0;\!?'#P9KWCWXE?&75?VK-#UG1Y
M_A3XL_;$\ ^"_A1\#X?&TA\27EAK'PST3P!\0OB]X/\ #7B[PU!::=!9Z[\?
M/B2 _C"X\):M\);6P\;&*#2?[X=8T?2/$6D:KX?\0:5IVNZ#KNG7VCZWHFL6
M-MJ>D:QI&IVTMEJ6E:KIM[%/9ZAIVH6<\UI?6-W#-;7=M-+!/%)%(Z'_ "/O
M^"G?P"\%_LO_ /!0#]K#X%_#?[-%\/\ P+\7_$">"M,LWO)K?PWX6\1):^+=
M"\'1W.H7^IZA>?\ "$Z;KUOX1>_U"_N;^_DT5KR\<7,\J+X^28ZAQ+0QN30H
MRR2V'E7@LJ=.C0JPYX4INO'V*G.5YTH58NMRXBE*2M3E'G?QG 7$.7^*F79[
MP-0P53@%0R^ICZ4.#Y8;!X'%4G6H86O+&T5@H5ZL^:MAJ6+I/&*GF.%J5(-8
M>I259_ZZ5?XI>H:A?ZM?WVJZK>WFIZIJ=Y<ZAJ6I:A<S7M_J%_>S/<WE]?7E
MR\EQ=WEW<223W-S/))-/-(\LKL[,Q_TQ/^#;C]J/Q_\ M.?\$T/#,'Q)GN]6
M\0?L[_%#Q9^SC9>*M2U,ZEJGBOPIX3\->!O'/@RZU &RM/L4GACPO\1]*^'=
MI 9=1GN],\%6&L7VHS:AJEW'!_"/_P %9/V3-2_8M_X*!?M)_!;_ (1>'PMX
M&D^(.M?$+X,VFF6&M6GAJ3X+_$>_N?%GP\L_#%YK5I:OK-CX0TG43\.]:O[!
M[_3K7QGX,\4:%%J5Y<:-<R4^!Z?]FYMGF4UW%XF'LN64?AG#"U*T)R@][36(
MHU%%VDH_%%.+27@'A?\ 5;C'Q X-S"=*6:T%@G2JTVO9XBAE&)QM&O5HMWDH
MUXYG@L1&D[5(T[JK",Z<E'^Z_P#X-G-&T?2_^"3'PBOM,M[>&]\2?$GXW:UX
MBD@C1);K6(/B+K'AZ">\9 &EN%\/Z#H5JLDI9Q:6UK$#Y<<8'[\U_*E_P:6?
M&32?%7[$OQY^"4WB"[U'Q?\ !_\ :(N/%<F@SVUV+;PY\._BYX&\,KX0-C?/
M;I831:QXW^'OQ:NYK&WNI[RRN8I;J^AMH-3TYKC^JVOAN(J4Z.>YM"?Q/'XB
MJM&O<KU'7I[I/^'4CTL]TVK-_P _>)V$KX'Q"XQHXA/VD\_S#&1O&<7[#,*\
ML?AM)J+L\-B:3BTN22M*FY4W&3*_Q9?&NFZ9HWC+Q;I&B3_:M&TKQ-KVFZ1=
M>:)OM.EV.JW=K87'G+\LOG6D44GFKQ)NWC@U_LA_'CXN>'_@#\$/C!\<_%BS
MR>&?@W\,/'GQ0U^&U59+RYTGP'X7U3Q/?6=C$\D*SW]Y;Z8]K8V_FHUS=S0P
M(P>1:_QEJ^U\.*<[YM5O)4[8.FE9\DYWQ,F[_P U.-M.BJ]+Z_O'T7L/6OQG
MBVZD<.UD6'BN5^RK5HO-:LGS7LZF&A*&EFU'%7;5U?\ TF_^#8/Q#K^J_P#!
M*?P]8ZG+//9^$OC;\9M#\*13,S1P:+/J&E>*9K>U!X2!_$_B/Q#.RKP;JXN7
M^\S5_FR5_K+_ /!(']ESQ!^QU_P3D_9?^!_C.RDT[X@6'@F[\<_$33KO3X].
MU31O&OQ5\1:Q\2M:\*ZU#%+.LVK^!&\4P^ KN[$TBW/_  BZ2Q%83&B_YJO_
M  4Q_9(U3]B#]N+]H;]GF;0YM$\)^&?'VKZW\)@]SJFIV^H?!CQA<R>)?A9=
M6^MZM!%<:W<V?@_4M,T+Q'>++?+:^,-&\1Z--J%Y>Z5=S-V<'XW#UL]XGC3F
MI?7,4\7AVK<M2C2Q6+4IIWU;^LTI*R>C;;TU]OP6S[+,;XA>+%/#5H3_ +:S
M;^ULME!Q]GB<#@\USB%6O!\RE)U/[4PE:*C&5XU)RE)67-_H+_\ !N9865G_
M ,$=OV3;BUMHH)]5O/C_ '^I2QH%>\O8_P!I;XP:7'<W!'+S+IVFV%HK-R(+
M6%.B"OV\K^8?_@U,^.-OX_\ ^"?7CSX.7WB2TO\ Q'\ ?CWXHM++PPO%_P"'
M/AO\3-&T7QMX9U"X41JIL?$/C]_BZ+&5I))6N-'U.-@D4,&[^GBOSOB"G.EG
MF;QFK-YCBZB7]RM6G5IOYPG%_,_F?Q)PM;!^('&5*O%QG/B3-\5%._\ !QV-
MJXW#RUMI+#XBE)=+/2ZLPK_$_K_9&_:F^-VF?LU_LU_'O]H'5Q#+9_!KX1?$
M'XCK9S36T']K7_A/POJ>L:3H-L]Y<6MN^H>(-6M;+1-,MI+F'[9J.H6MHCB2
M9*_QO(XY)9$BB1Y)9'6...-6>221R%1$106=W8A5502Q( !)K[OPWC)0SBHU
M:$I8&*D]G*FL9*:_[=52#?\ B1_0?T7J-6%#C;$R@U0JU>'Z,*C^&53#PSFI
M6CZTX8FA*7E41_IN_P#!M?J6I7W_  2*^ %M?*XM='\8?'73=&+ X;39?C-X
MUU>5DSU7^U]5U521QO5QU!K^2'XP?\K,.D?]I7O@;_ZO_P"']?W>?\$K_P!E
MO5_V,?\ @GW^R_\ L[>)EN8O&7@[X?-KGCZSO'T^>XTCXA?$K7]:^)_COPW]
MKTLO97UKX4\6>,M7\+Z;?0RSB[TO1K*8SS%S(W\(?Q@_Y68=(_[2O? W_P!7
M_P##^N#A^M3Q/$'%&(I/FI5\#G-:G+^:G4QM*<)?]O1:?S/"\-L=ALS\0_%[
M,<'-5,)C\EXRQF%JQVJX?$YU2K4:JM=?O*<XST;^+=G]S'_!4?\ X)M?"G_@
MIA^S?JOPH\8P:?H/Q1\*QZIXB^ OQ8:VSJGPY\>3VD2&&YN8()KV[\!>,/L6
MGZ3\0O#2I/!JNG6VG:S:6\7BOPOX3U?1_P#+&^-?P8^+O[+7QH\:_!?XO>&=
M9^'/Q>^$_B4:3XAT6XE\F_TG5;5+;4]*U;2=3L96@O\ 2]5T^YTWQ'X6\2:1
M=3Z9KFAZAI6OZ)?76G7UG=R_[+]?@?\ \%T_^"06G_\ !1SX.P?$[X0:9I.G
M_M@_!G0+\?#^YF;3=(3XO^$(I)]5N?@UXCUZ]>TMK2YDO9;W4?AGK&NWT.A>
M'?%6I:GI^J7>AZ#XP\0>(=*X>$>)7E5;ZAC9.66XF5KRLUA*LVE[77_EQ/:O
M#:/\6.JG&I\[X+^*;X1QJX=SVLY\+YG6M"K5E>.2XRM)1>)7-HLOQ#=L?2TC
M2D_KL+26)AB?SU_8E_X+*Z?^WM_P2S_;B_9S^/>KQ6/[8/PE_86_:6DFU>\E
MMX;3]H'P%IGP3\9VB>/](7>KP_$'08_LMK\4/#OE>3>R36?CWPU++INL>(_#
MGP__ #!_X-+/^4C7QI_[,G^(W_J]?V;Z_FDE'COX7>+==TF=?%?P\\<^')_%
M7@GQ-I=PFK^%/%6AW-Q::IX-\<>$-?L)18:MILMQ87>M^%/%GA[4H86FL[K5
M="UBS:">\M6_I;_X-+/^4C7QI_[,G^(W_J]?V;Z^RS+)L/E.3\2U<&XQPV/H
M4JU.C%>[0E'F52--IM.E)S4Z:5E!-P2Y8Q;_ ''BO@G+.$.!?%'$9*X4\LXA
MP>'S&C@:<?W6!JP]RO3PTDW%X2K*I&MAX1Y8T(SE0A%4:=*_]I/_  5'_P"4
M;'[?'_9GW[17_JJ/%5?Y%U?ZZ/\ P5'_ .4;'[?'_9GW[17_ *JCQ57^1=7%
MX<_[EF7_ &%4O_33/G_HQ?\ (AXG_P"QOA/_ %#9_6Y_PTW_ ,':_P#T+?[0
MG_B)'[,/_P Y>O>OV5OVB/\ @Y^UK]J#]F_1OCYX?^.D/P*U;X]?!_3/C3-J
MW[+W[.F@:5%\)K_XA>';7XC2:GKNB?"33=9T73T\'RZRU[JVD:C8:IIML)+R
MPO;6[ABG3^VJBOC)\2J<)P_U?X;ASQE'GAE?+./,FN:$O;/EG&]XNSLTF?A^
M(\5</B,/7H+PT\,:#K4:M%5J'#%.G7H^TA*'M:,_;ODJT^;GISL^6:3MH%%%
M%?,'Y(?XG]?ZXW_!*O\ Y1I?L%?]FD_ 3_U6_AZODC_AW_\ L&_]&2_LC?\
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M+]0\4:W+K'QA^ RQ_ /XN3:A>7EYK.K:CX(TVP7P5XVU&\U;5]7UW6[OQO\
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M<NE[/V?LLIPE&W/S\W+.O+FORQM?FM;6UMS]8\7,Y_MG,^&*OU;ZM]4X.RG
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M=U>6EL]R\:SW5O$6E3^\S_B+9_X)_P#_ $0;]L3_ ,)#X*__ #]*^Z_^'?\
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M3XP:5)BX\&:5X-N?LNH>&_AKJ*0>,M6\8V\=YXYLO"FA>%AX;^(_[)?\&_\
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MK[K_ .'?_P"P;_T9+^R-_P"(V_!O_P"8RC_AW_\ L&_]&2_LC?\ B-OP;_\
MF,J_[&X?_P"A?BNG_,QEUY?^H?\ O&_^I'AQ_P!$UFW3_FIZW]W_ *EOG^!\
M*?\ $6S_ ,$__P#H@W[8G_A(?!7_ .?I17W7_P ._P#]@W_HR7]D;_Q&WX-_
M_,911_8W#_\ T+\5T_YF,NO+_P!0_P#>#_4CPX_Z)K-NG_-3UO[O_4M\_P #
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image00005.jpg
<TEXT>
begin 644 image00005.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !: %H# 2(  A$! Q$!_\0
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MN]2I%/717?0_G'HK^Z3XO?\ !NU_P1I_9]_X1[_A??[;WQH^"/\ PEW]K?\
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M>WFB\/>-O#^LZIX/\56<SOIVK>&=<U?2-6MKO2KZ\M)O]"K_ (*R_P#!/?\
M8Q_;4\-?"3X@_ML_'_Q)^SS\.?V?7\<V.E^+M-^)7PJ^%'AJ75/C%J'PXTY8
M?%/BWXM>%/%&A1.UYX'TK3= L+<Z9<7VH:O)")KF4VUNWS)^PI^R-_P1R_97
M\6Z#?_L#?$_]EC]I[]MJ#0/%^B_#75OB3^VEX/\ %?Q$\4QZG%=:SXJ_LZQ^
M&NG^.] \&ZCI/@.QURQG\7?##]GG_A*(O UIKVCZM>-HGB#QC?WV. S?#X?)
M8X9T:]>K&GB83C&D_8KVE2M->TJMJ,8<M2/.]7%/8\_A7C_*LJ\.*.2_V;FF
M98ZGA<YPE:%+!M9;3EC<7F&(B\9F%6<*%+#1H8FE+$S7/*E"=W#E4I1_:;]I
MN7X10?LV_M!S_M Q7$_P%A^"'Q8E^-T-HOB)[J;X11^ ]??XDQ6R>$&7Q8]Q
M)X-&M)"OA=E\1-(5&BL-2-L:_P ?:O[5_P#@O]H/_!:/XF_"#5;;Q/\ "OX4
M:1^Q%X?CB\??$7PQ^R?X\\7?%K6;2W\+V?A_4EN_VA_$7C?P1\*/&WC#PGX(
M\0Z#KWQ'TBZ\!_!_PS\-/!^F7%EK'Q0FUK7_  %X6\7:9_%17H<,87V&%K5?
M;4ZCKSA>G2J1J1H^S4K*;BVE5ESMR2^RJ;N^GUO@GD?]EY'F&->:8/&U,TQ-
M!SPF!Q=/%TLN^JTZL5"O*E*4(8VM[=NM"+E'V-/"N-2:?NE?Z8?[)W_!9G]@
MQ_V6/V:7^.?[:_PN'QL?]G_X-O\ &$>(=2O8_$ ^*;?#KPX?B"-<CM-&6T36
M/^$M.K_VFEJJVZWOGK"HC"BO\SRBO1S3*J6:1HQJ5)4G1E.490C%M\Z2E&\M
MD^6+=MVE?9'V7&W V XWH8"CC<5B,&\OK5ZM*MAJ=&=5K$0A"I3<JT).,).E
M3E)1MS2A!RORQM[K^U%\)=.^ 7[3'[1/P)T?5KW7])^"OQU^+GPETO7M2@@M
MM1UO3OAQX_\ $'@ZRU>_MK7-M;WNI6VC17EU!;DP13S21P_NU6O"J_HK_P"#
MF;]EC6O@I_P4#F^.]O K?#_]K3P;HOC'1;FVTO3-(T_3/'_PUT'PY\.?B/X4
MACL]4NKW5[Y+6P\$?$?5_$5[I6BQW]_\49-.A34KS1M3U.X_G4KJP&(6*P6&
MQ"?,ZE&#D[W_ 'B7+43:2NXU%*+T6J>BV/9X7S:&><.Y-FT)JH\;E^&J5I*7
M/RXJ,%2QE.4E&"E.CBZ=:C-J$4YPE:*V/] O_@U*_P"4>/QE_P"SS_B'_P"J
M/_9UK\B?^#L#_D]K]GO_ +-8TO\ ]6U\4J^]?^#:#]K3]E;X#_L)?%CPA\<?
MVF/V?O@SXLU']K7QWXDT_P +_%?XR_#GX=^(K_P[>?!WX#:9::]9:)XO\2:/
MJ5UHMUJ6CZOI]OJD%L]C/?:7J-I%.UQ8W,<7Y;_\'-'QS^"?QZ_:_P#@7XF^
M!GQA^%GQH\-Z1^S;INA:MX@^$_Q!\)?$71-,UN/XG_$C4'T;4=5\'ZOK%A9:
MJEA?65Z^GW-Q%=K:7EK<F$0W$+O\QA:=1<3XBHZ<U!NO:;A)0?[I;2M;\3\2
MR'!8R'C9F^*GA,3'#2J9IRXF5"K&A+FP<5'EK."IOF>BM+5Z(_F]K^XW_@TG
M_P"2*_MD?]E1^%W_ *B?B6OX<J_L;_X-@OVGOV:_@#\(OVK]-^._[0OP-^"F
MH^(_B/\ #B^\/:?\6_BSX"^'%[KME8^&?$%O>WFC6OC'7]&GU2ULYYH8;JXL
MHYX;>66*.5T>15/L<0QE/*L1&$93DY4+1C%R;_?T]DKMGZ#XN4*^(X$S6EAZ
M-6O5E7RUQI4:<ZM27+F.&E+EA!2D[13;LM$FWHCH?^#N[_G'Q_W=A_[[57\:
M>D:OJWA_5=,U[0=3U#1-<T34++5]&UG2+VYTW5=(U73;F*\T[4],U&SEAO+#
M4+"\AANK*]M9HKFUN8HIX)8Y8U8?Z,?_  49\"?\$:?^"G7_  IS_A??_!2;
MX,>$?^%(_P#"PO\ A%/^%0_MB?LKZ!_:'_"RO^$'_MW_ (2'_A,[/Q]]K^R?
M\(#H_P#9/]F_V3Y'VG4_MGV_SK7['\6_ 7_@F'_P;D?!'XCZ7\1=;_;I^#7[
M0*Z&MM<:3X"^/7[:_P"R_K7PXAUVPUW0]<T[Q!JGAKX?67PVD\6M:C1Y]&N?
M"?C;4?$GPXU_0M>URP\4^"M=,FG3Z;Y>59K1P664,/5P^,E6I*M>$,--J7/7
MJ3BE)VCK&<;W>FOE?XK@?CG+N&N"\MRC'Y3Q#6S#!0S'VN&P^38F<*CQ&98W
M%4H1K5%3I6E2KT^=R:4;R6K5G_1W^Q-X^\:?%7]C/]D?XH?$C69?$?Q$^)'[
M,?P$\>^/?$,^FZ3HTVO>-/&'PJ\*>(?%.LS:1H&G:/H.E2ZIKFHWU])INB:3
MI>D6+SFUTW3K*SBAMHO\KW]M7X=^#_A#^V3^UK\)OAYI#>'_  !\+_VFOCS\
M._ V@MJ.K:PVB>#O!/Q4\5^&O#.D-J^O7VJ:YJITW1-,L;,ZCK.IZCJU\8?M
M.HWUW>2S7$G]R/[</_!RW^QG\$O!&N:1^R3JC?M2_'"X/BW0-&\GP]XR\+_!
MWP/X@T66WTRR\0^-?%'B/2O"U[X]\.W%]=SZIH.G_"236[#QMIWA_4K67Q_X
M#M-8\.>)[[_/M\1^(_$/C#Q#KOB[Q=K^M^*_%GBG6=4\1^)_%'B75;_7O$?B
M3Q#K=]/J>M:_K^N:K<7>J:SK>L:E=7.HZKJVI75S?ZC?7$]Y>7$UQ-)(U<-8
M/%4)XO$5J,\-2K\JIT9IP;:G.2?LVHM1IJ7+&4HQYE)\FES?P;X>SO+L3Q#G
M&89;B,FP.:.C'!Y?B(2P\Y.&(Q-52^JRC2G"EA:=3V5"I5H4E4A6DZ"]GS7Q
MJ_LP_9=_X-B/@/\ 'W]F?]G;X[:Q^T]\7- U;XU? KX1_%K5-!TWPCX-N=.T
M34?B/X \/^,;W2+"YNG%S<66FW.LRV=K/< 3RP0QR3?O&:OY9_V-OV9_%/[8
MW[4GP/\ V9O"$US9:G\7?'NE^'=1UNTL[+4I_"G@^V6?6_B#XX72M0U?0;?6
M$\"> ]*\2>,9M%&L6%UK$.AR:983?;[NV1_]=6PL+'2K&RTO2[*TTW3--M+:
MPT[3K"VAL[&PL;.%+>TLK*TMTCM[6TM;>.."VMH(XX8(8TBB1455#XES*OA'
MA:.%K2I59JI5J.#5_9Z1IW33TE+VEGIK![]-/&7C+,^'I9)E^29C5P..Q"Q6
M,QCH.FYK")PH893A4I5$XUZRQ/)).+3PTTU+FO'\KO\ @L5_P3QT7_@H?^Q_
MXN\&:-H=C<?M _"^RUGXB?LYZ\MCH0UM_&^GZ=Y]]\,(]<UO6/#5KI'AOXR6
MEA:^#]:EU/Q)IWAG2=>'@[Q_K]IJ[> -,LC_ )?GB+P[XA\'^(-=\)>+="UG
MPOXJ\+ZSJ?AWQ-X9\1:7?:)X@\.^(-$O9],UG0M=T;4X+;4=(UG2-2MKG3]3
MTS4+:WO;"]MY[2[@BGBDC7_9?K^3'_@N_P#\$,;GXY2>,/VW?V,?"L]S\;%A
MFU[X\? G0+62:3XRV]G;C[;\2/A=I-NK,/C#:6D E\6>!=/BV?&"WA?6_#%J
MOQCCO]+^,WF<.9O'"R>"Q,^6A5ES4:DG[M*K*R<)-Z1IU+7OI&%2[EI.4H_$
M>#_']')*TN&LYQ"HY9C*SJY=BJLG[+ XVJXQG0JSD[4<)BFE)3TIT,5S5*B4
M,36K4_X5:***^^/ZK"BBB@ HHHH ***_H?\ ^")?_!$SQ%^WKXBTS]HG]HC3
M-:\*_L8^%=:F2TM$EOM#\1?M)^(M#OGMM0\'>#M0MGM=2T?X8Z/J5K/I?Q)^
M).ESV]]<7UO?_#CX<7\/C*'Q?XO^$O-B\70P5">(Q$^2G#YRG)_#"$=.:<K:
M+UE)J*DUX^>Y[EO#F68C-<VQ"H86@K)*TJU>M)/V>&PU.Z=7$56FH03224JE
M25.E3J5(?KO_ ,&S/_!,Z;X=>"M2_P""@7QR\"W6F^/_ (A6D_A[]F32_%WA
MZPCO?#WPHU+2[5];^-GAZ2ZU&]U/3;SXLKJ-YX1\+7]QH/A;64^&^CZYK&BZ
MEXE^'_QHM)Y/ZXJS-$T31O#6C:1X<\.:1IGA_P />'],L-$T'0=$L+72M&T3
M1M*M8K#2](TC2["*"QTW3--L8(+.PL+."&UL[6&*WMXHX8T0:=?EF/QE7'XJ
MIB:NCF[0A=M4Z<=(0C?HEJVDN:;E.R<F?POQ1Q%C.*<[QF<XWW98B:C0H*4I
M4\)A*2Y,/AJ5]%&G#WJCC&*JUYU:[BIU9!1117&?/GX3_P#!3+_@@O\ LP?M
M\W.J_%3P//'^SC^TJ^GZD6\>>"O#VCGP'\3-:O\ 7K779M4^-G@>TM+"Y\3^
M(9$;Q#IUM\0/#VN>'?&*R^)(M0\97'Q&TOPGX8\*6?\ #Y^V#_P2:_;U_8>3
M6M;^-WP&\0S?#31[[58?^%T_#IXOB)\)I=+T_7=/\/6'B/5_$OAL75W\/-*\
M4:AJ^DKX5L_BSI'P_P#$FLG4(K5- BU*WO[&S_U6Z*]S+\_QN!C&DVL10C9*
ME5OS02Z4ZJ]Z*V2C)5(12M&"O<_3^$_%?B3A>E2P4W3SC*J5HPP>.E-5L/35
M_P!W@\;'FJT8_"HTZ\,50I1CRT:-.[;_ ,8>BO\ 3%_X+,_LG_LLR?L&_MK_
M !SD_9I^ $GQL'PMU/Q"/C"_P;^'3?%,:_%>:/9Q:X/B"WAP^+1K$=HB6L>I
M_P!K_;4MU6!9Q$H4?YG5??9?C?KU%5O9>RNJ;Y>?G^."GOR0VO;;6U]-C^JN
M%.(_]9\MAF/U/ZCSPP\_8_6/K-O;X>%>WM/88>_+S\M^1<UN:RO9%?3/[,_[
M&O[4O[8_BB7PC^S-\#O'OQ=U*RN;2SUK4O#VEK;>#O"EQJ%CJ^HZ6OC?X@ZY
M/I7@+P*NKVVA:N-&E\8^)-#AUFZL9;#3)+N_,=L_]3'_  ;$?LN_LS_'WX#?
MM/:Q\=OV=O@5\:M7T#XN^$M-T+5/BU\(_ 'Q'U'1=.N?!K75QI^D7WC'P_K-
MSIME<7/^D36MG+#!+/\ OGC:3YJ_L\L+"QTNQL],TRRM-.TW3K2WL-/T^PMH
M;.QL+&SA2WM+.SM+=([>UM+6WCC@M[>"-(8(42*)%154>1FV?5,ODZ5/#0G-
MN<8U)U)<B<%3=W3C!.2?/LJD;6WU/@N//%+$\)UY8#!Y/0Q.)G*O3I8K$XRI
M["G*C##R4ZF$I4(5*L9>WMR1QE%KEOSOFLOY*O\ @FA_P;+^"OAO<^"/CA_P
M4 U6Q^(WCW2[S0/%FE?LT>&YM.U'X2Z%>16.HW+Z#\:M;GL[UOBQ=:?J=YH-
MS?>%?"MQHOPZ36/"^HZ-K6M?&;P!XDN+)_ZS=$T71O#6C:3X<\.:1IF@>'M
MTRPT30M"T2PM=*T;1=&TJUBL=+TG2=+L8H+'3=,TVQ@@L["PLX(;6SM88K>W
MBCAC1!IT5\/C,=BL?4]KB:KFU?DBO=ITT_LP@M(K9-ZRE9.<I/4_F/B+BC.^
M*<9]=SG&SQ,X\RH4(I4L+A:<G?V>&P\+0IJR2E-J5:KRQ=:K5FN8****Y#Y\
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
